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CHAPTER 1 INTRODUCTION 
1.1: Nanotechnology and Magnetic Nanoparticles 
Nanotechnology is an emerging field of science, which includes the study of materials 
with size ranging from few nanometers to several hundred nanometers and their applications to 
various fields. Nanomaterials are of great scientific interest as they are effectively a bridge 
between bulk materials and atomic or molecular structures and interestingly, the properties of 
materials can change as their size approaches the nanoscale. In recent years, nanoparticles have 
attracted a great deal of attention due their potential applications in biomedicine [1-5]. Among 
nanoparticles for such use, magnetic nanoparticles have the potential to be delivered to a specific 
region in the body with an external magnetic field manipulation. This requires large 
magnetization for the magnetic nanoparticles so that they respond to externally applied magnetic 
field at physiological temperatures. Iron oxide nanoparticles (Fe3O4), with relatively higher 
saturation magnetization values are therefore suitable for this purpose. Furthermore, low toxicity, 
biocompatibility, surface functionalization capabilities combined with excellent magnetic 
resonance imaging (MRI) contrast property make them ideal for use in noninvasive disease 
targeting, detection, and treatment. Therefore, superparamagnetic Fe3O4 nanoparticles are 
currently used as one of the most important and acceptable candidates for magnetic resonance 
imaging (MRI) [6-8],targeted drug delivery [9-11], magnetic hyperthermia [12-14], and cell 
separation [15,16].Nanoparticles have higher surface energy due to their smaller sizes hence tend 
to form agglomerates which is not favorable for their use in clinical applications. Therefore, 
these nanoparticles are often coated with a surfactant making them a stable colloidal suspension 
which is called a “Ferrofluid”. 
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1.2: Magnetic Hyperthermia  
 Over the past decade, the topic of “cancer therapy” has attracted a great deal of attention 
due to the huge impact it has on human life. The principle of cancer treatment is to kill the 
malignant cells with the least of damage to normal cells. Distinguishing cancer cells from normal 
cells is difficult, making the existing treatments such as chemotherapy and radiation therapy less 
effective and fraught with various side effects Hyperthermia or heating therapy has great 
potential as a complimentary cancer treatment method. It is known that the blood flow in tumor 
is lower and the reduced blood flow causes the lack of oxygen which leads to the formation of 
lactic acid making the cells more acidic [17]. The acidic cells which are more sensitive to 
temperature, have lower thermal resistance than normal cells and the decreased blood flow in the 
tumor limit their ability to dissipate heat. As a result, cancer cells can be damaged and killed by 
increasing the local temperature to the range of 42 ºC to 46 ºC with little detriment to healthy 
cells. Depending on the  nature of the heating source and the heated target, hyperthermia is 
categorized into 3 types: local, regional, and whole body hyperthermia [18] .Whole body 
hyperthermia is used only when the disease has spread throughout the body and can be achieved 
using hot wax, hot air, hot water suits, or infrared radiation. Regional hyperthermia where heat is 
subjected to a smaller area such as a whole tissue or organ is accomplished by utilizing 
ultrasound, radio frequency (RF) fields, or microwaves. Local hyperthermia involves heating a 
small area of interest such as a tumor. Different approaches for inducing hyperthermia as 
discussed above are illustrated in the Figure 1.1. The effectiveness of the treatment is judged by 
how much of the tumor is heated to a therapeutic level and often this is very low due to lack of 
heat transfer to the tumor site.  
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Figure 1.1: Methods of achieving hyperthermia for cancer treatment [19]. 
Various nanoparticles have been used as heat mediators in local hyperthermia technique.  
The most common types of nanoparticles which have been investigated for hyperthermia therapy 
are listed in Table 1.1.   
The idea of utilizing magnetic nanoparticles for hyperthermia was first proposed by 
Gilchrist et al. in 1950s and since then many types of nanoparticles show promising results [19]. 
Magnetic hyperthermia, where electromagnetic energy is converted into heat by applying an 
external alternating magnetic field on magnetic nanoparticles, is of particular interest as the 
nanoparticles can be guided and localized specifically at a tumor site by external magnetic field 
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guidance and can also be directed to the cancer cells by tagging a targeting ligand such as 
antibody or peptide, without reducing its efficiency [20,21]. For example, Fabio et al. have 
reported that conjugation of folate receptors enhances the targeting for magnetic hyperthermia in 
solid tumors [22].   
Table 1.1: Commonly studied nanoparticles for hyperthermia 
Meterial Structure Hyperthermia type 
Au  Nanorods [23,24], 
Nanoshells [25,26] 
Photothermal heating 
(NIR) 
Carbon  Nanotubes (CNT) [27-30], 
Graphene oxide sheets[31] 
Photothermal  heating 
(NIR) 
Quantum dots (CdTe, dSe) 
 
[32,33] Photothermal heating 
(Radiofrequency) 
Fe3O4 Nanosheres [34-36] 
Nanocubes [37-39], 
Coreshell [40,41] 
Magnetic heating 
Magnetite (Fe3O4) and maghemite (γ-Fe2O3) have been extensively studied and are 
promising candidates due to their biocompatibility and relative ease to functionalize. Figure 1.2 
illustrates an example of strategy for using magnetic nanoparticles as a potential Theranostic 
(Diagnostic + Theraputic) agent. Recent studies have reported the heating efficiencies in Fe3O4/γ-
Fe2O3 core-shell structures as well [42]. Additionally, iron oxide nanoparticles doped with other 
magnetic dopants such as Co, Mn and Ni [43-45] are under investigation to achieve a high heating 
efficiency by tuning the magnetic anisotropy and saturation magnetization of the material. 
However, among numerous complications, with a high curie temperature of Fe3O4 -850K and γ-
Fe2O3- 750 K, overheating is one of the drawbacks of utilizing these nanoparticles and as a 
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solution for those complex magnetic oxides with low Curie temperature are being investigated 
[46-48].  
 
Figure 1.2: Schematic illustration of the therapeutic strategy using magnetic particles. 
Functionalized magnetic nanoparticles accumulate in the tumor tissues via the drug delivery 
system (DDS). Magnetic nanoparticles can be used as a tool for cancer diagnosis by magnetic 
resonance imaging (MRI) or for magnetoimpedance (MI) sensor. Hyperthermia can then be 
induced by AMF exposure [49]. 
1.3: Magnetic nanoparticles based drug delivery 
Over the last two decades, magnetic nanoparticles have been increasingly exploited as 
platforms for transport of drugs and genes [50,51].  In magnetic drug delivery, a drug or 
therapeutic reagent is conjugated to the nanoparticle and introduced in the body, and 
concentrated in the target area by means of a magnetic field gradient (using an internally 
implanted permanent magnet or an externally applied field) [52]. Using a targeting ligand the 
targeting specificity can be enhanced. These anti-cancer drugs carried by the nanoparticles can 
then be released at the tumor site via enzymatic activity, or via changes in the physiological 
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conditions such as temperature and pH.  Drug release can also be magnetically triggered from the 
drug-conjugated magnetic nanoparticles [52-54]. For example, Hayashi et al [55] reports a study 
done on superparamagnetic iron oxide nanoparticles conjugated with folic acid (well-known as a 
targeting ligand for breast cancer cells), β-Cyclodextrin (which act as drug container)and 
tamoxifen (anti-cancer drug). By means of an AC magnetic field, heat is generated which 
triggers drug release - a behavior that is controlled by switching the high frequency magnetic 
field on and off. This is capable of performing drug delivery and hyperthermia simultaneously. 
Among various other anti-cancer drugs doxorubicin is widely used as a model drug. There are 
several methods that can be used to load doxorubicin into nanoparticles such as by adsorption on 
the nanocarrier inorganic core [56-58], by diffusion [59,60] or entrapment [61,62] in the coating 
materials and by chemical bonds [63,64] with the coating of the nanocarrier. Even though 
magnetic drug delivery shows a great promise in cancer treatment avoiding the side effects of 
conventional chemotherapy, the designing and fabrication of an efficient nanoparticle based drug 
delivery system is still a challenge.  
1.4: Surface modification of magnetic nanoparticles 
Nanoparticles have larger surface to volume ratio and hence possess high surface 
energies. Moreover magnetic nanoparticles which are of interest for biomedical applications such 
as magnetite (Fe3O4) have hydrophobic surfaces. Therefore, these particles tend to aggregates 
forming large clusters resulting in increased particle size and in addition, exhibit high chemical 
activity which causes them to easily oxidize in air (especially magnetite)generally resulting in 
loss of magnetism and dispersibility. Therefore, providing a proper surface coating to keep the 
stability of the nanoparticles is crucial. Additionally, in order to expand the scope of biological 
application of nanoparticles, some molecules/surfactants are also employed to enhance its 
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biocompatibility. The stable colloidal suspensions of surfactant coated iron oxides nanoparticles 
are called “Ferrofluids” which are magnetizable fluids that remain as liquids in the most intense 
magnetic fields and in biological media. Stabilization of the ferrofluid can be achieved by the 
presence of one or both of the two repulsive forces (see Fig. 1.3): electrostatic and steric 
repulsion between the particles [51]. The steric force is difficult to predict or quantify and mostly 
depend on the weight and the density of the polymer used for the coating. The electrostatic 
repulsion can be understood through the knowledge of the diffusion potential and mainly 
depends on the ionic strength and the pH of the solution.  
 
 
Figure 1.3: (a) Particles stabilized by the electrostatic layer and (b) Particles stabilized by steric 
repulsion [51]. 
Over the years, researchers have developed various surface modification strategies 
comprised of grafting of or coating with both organic and inorganic materials. In addition to the 
stabilization, these protecting shells also provide a platform for further functionalization 
depending on the desired application. The coating process can be done during the nanoparticles 
synthesis referred to as “in situ” coating or can be done after the nanoparticle synthesis referred 
as “post-synthesis”. Organic molecules include small organic molecules, macromolecules or 
polymer and biological molecules. They provide various highly reactive functional groups such 
as carboxyl groups, aldehyde groups and amino groups. Moreover, organic compounds 
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functionalized nanoparticles preserve the basic magnetism characteristics of magnetic 
nanoparticles as well as possess good biocompatibility and biodegradability.  
Based on their surface characteristics functionalized nanoparticles can be divided into 
three main types; water soluble, oil-soluble, and amphiphilic. Nanoparticles with surfaces 
containing hydrophobic group, such as the fatty acid, alkyl phenol are referred to as oil-soluble. 
Examples for such surfactants are oleic acid, myristic acid, lauric acid, hexadecylphosphonic 
acid, dihexadecylphosphonic acid etc [65,66]. Nanoparticles with chemical groups which are 
hydrophilic on the surface are called water-soluble and some examples are citric acid [67],amino 
acid [68]. Amphiphilic type refers to the nanoparticles with surfaces containing both hydrophilic 
and hydrophobic chemical groups, such as cyclodextrin [69], sulfuric lycine [70] which make the 
functionalized nanoparticles both oil-soluble and water-soluble. Polymer coated nanoparticles 
are also of great interest for their use in biomedical applications.  Polymer coating materials can 
be classified into synthetic and natural and some commonly used polymers are listed in Table 1.2 
along with their advantages.  
Table 1.2: Commonly studied Organic polymers and their advantages. 
Polymer Advantages and applications References 
Natural Dextran Stability, Biocompatibility, Enables 
optimum polar interactions with iron oxide 
surfaces, Enhances the blood circulation 
time. 
[15,76-80], 
Starch Improves the biocompatibility, good for 
MRI, and drug target delivery 
[81,82] 
Chitosan Biocompatible and hydrophilic large 
abundance in nature, biocompatibility, and 
ease of functionalization. widely used as 
non-viral gene delivery system 
[83-86] 
Synthetic Poly(ethyleneglycol) 
(PEG) 
Enhance the hydrophilicity and water-
solubility, improves the biocompatibility, 
blood circulation times and internalization 
[87-89] 
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efficiency of the nanoparticles. 
Used in target-specific cell labeling, 
Magnetic hyperthermia, targeted drug 
delivery 
Alginate Improves the stability and 
biocompatibility. 
Used in drug delivery applications. 
[90-92] 
Poly-N-
isopropylacrylamide 
(PNIPAM) 
Generally used as thermosensitive drug 
delivery and cell separation 
[93-96] 
Polyethyleneimine (PEI) Ability to complex with DNA, guide 
intracellular trafficking of their cargo into 
the nucleus, used for gene delivery cell 
transfection with either DNA or siRNA 
nucleotides. 
[97-100] 
 
Also depending on the properties and the structure, coating arrangement of polymers on 
the surface of nanoparticles can be different as well (Fig. 1.4). 
 
Figure 1.4 :Illustration depicting the assembly of polymers onto the surface of magnetic 
nanoparticle cores [75]. 
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Depending on the desired application, these nanoparticle can be further modified by 
functionalizing them with various biological molecules such as antibodies, proteins, targeting 
ligands, etc. [71-74].These may be bound to the polymer surfaces of the nanoparticles directly or 
indirectly by chemically coupling via some functional end groups such as amide or ester bonds 
to make the particles target specific. Inorganic materials are used for surface coating of the 
nanoparticles, mainly iron oxide nanoparticles. These inorganic materials include silica [101-
104], metal or nonmetals [105-108] (gold, silver, platinum, palladium, iron, carbon), and metal 
oxides (Al2O3) or metal sulfides. The coating with inorganic materials produces “core-shell” 
structure with the nanoparticle core and coating shell. These coatings not only provide stability 
to the nanoparticles in solution but also help in binding various biological ligands to the 
nanoparticle surface. The surface modified magnetic nanoparticles which are stabilized against 
clustering and sedimentation, with enhanced biocompatibility can be further modified such as the 
addition of specific targeting ligands, dyes or therapeutic agents providing the particles a wide 
ranging potential in the biomedical area.  Among these various surface modification possibilities 
the right choice of functionalization should be carefully chosen to obtain a desired structure 
suitable for the intended application.  
1.5: Scope of the thesis 
This thesis includes the synthesis characterization and two major applications of 
superparamagnetic Fe3O4 nanoparticles in the field of biomedicine; magnetic hyperthermia and 
drug delivery. Based on the experimental data and analysis on Fe3O4 nanoparticles, we are able 
to determine the effect of particle size, polydispersity, anisotropy and dipolar interactions on the 
temperature dependent SAR, qualitatively and quantitatively. The cellular studies done on 
human pancreatic cancer cells include the cytotoxicity, time dependent cellular uptake and 
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distribution of Dextran coated Fe3O4 nanoparticles. A novel drug-dye –nanoparticle conjugation 
was designed and fabricated and its cellular entry and time dependent drug release were 
investigated as well. Chapter 2 describes the detailed background on nanoparticle magnetism and 
magnetic hyperthermia, and their relation to linear response theory. It also provides theoretical 
framework used to analyze and interpret the experimental data. Chapter 3 describes various 
synthesis methods and functionalization strategies and introduces the working principles of the 
key characterization techniques used throughout this research. In Chapter 4, the results of our 
investigation on the effect of magnetic dipolar interactions and size distribution of Fe3O4 
nanoparticles on temperature dependent magnetic hyperthermia of ferrofluids are discussed. 
Chapter 5 explores the effect of Gd-doping and Chapter 6 on the effect of biocompatible coating 
of Fe3O4 nanoparticles with dextran and citric acid on magnetic and temperature dependent 
magnetic hyperthermia properties. Chapter 7 describes our study on time dependent cellular 
uptake and intracellular distribution of dextran coated Fe3O4 nanoparticles functionalized with 
fluorescent dye, FITC. Chapter 8 describes our study on the dual conjugation of doxorubicin and 
FITC on dextran coated Fe3O4 nanoparticles and its cellular internalization and drug release. The 
summary and prospects for future study are described in Chapter 9.  
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CHAPTER 2 MAGNETIC NANOPARTICLES AND MAGNETIC 
HYPERTHERMIA 
2.1: Magnetism in materials 
The origin of magnetism in materials is due to both spin and orbital angular momentum 
of electrons in atoms/ions/molecules and interactions between them. The magnetic property of a 
material is described by a quantity called “magnetization” (M), defined as net magnetic dipole 
moment per unit volume of the material.  The magnetic response of a material to an external 
magnetic field (H) is further defined by Magnetic Susceptibility, 
χ = M/H        (2.1) 
In the absence of any magnetic ordering, magnetic materials can be divided into two 
categories; diamagnetics with small and negative χ (-10-6 to -10-3) and paramagnetic with small 
positive χ (10-6 - 10-1). Diamagnetism occurs when the atom has completely filled shells leading 
to a zero orbital angular momentum and zero spin. When an external field is applied, it alters the 
electron kinetic energy and thus their angular momentum. This leads to a net magnetic moment 
opposite to the applied field, while the spin remains zero. On the other hand, in a paramagnetic 
material, atoms have a permanent magnetic moment due to the net spin from the unpaired 
electrons. In the absence of external magnetic field H, all the magnetic moments are aligned 
randomly in different directions due to thermal fluctuation, resulting in a net zero magnetic 
moment. However, when an external magnetic field is applied, there will be anon-zero net 
magnetic moment, but returns to zero upon the removal of the external magnetic field. The 
temperature dependent behavior of paramagnetic susceptibility is explained using the Curie-
Weiss law [109]. 
Below a critical temperature, even in the absence of an external field, magnetic materials 
can develop long range magnetic order due to exchange coupling of spins (a quantum 
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mechanical effect) leading to a non-zero net magnetization. There are three types of basic 
magnetic ordering namely, ferromagnetic, antiferromagnetic, and ferrimagnetic. Figure 2.1 
shows the three simplest types of magnetic ordering. The critical temperature below which this 
long range order presents is known as the Curie temperature (for ferromagnets) or Neel 
temperature (for antiferromagnets and ferrimagnets).  
 
Figure 2.1: Arrangements of moments in magnetic systems (a) Ferromagnetic ordering 
(b) Antiferromagnetic ordering (c) Ferrimagnetic ordering 
It is well known that a bulk ferromagnetic material is composed of magnetic domains, 
regions in which all of the local spins are aligned parallel to each other, due to exchange 
coupling. The formation of magnetic domains is a result of balancing several energy terms: the 
exchange energy which tries to align all the magnetic moment along the same direction, the 
magnetocrystalline energy which arises from spin-orbit coupling and energetically favors 
alignment of the moments along specific direction, and the magnetostatic energy. The direction 
of the ferromagnetic spin alignment varies from one domain to another, and is randomly oriented 
in samples cooled through the transition temperature in zero fields so that the net magnetization 
is zero or small. The different domains in a ferromagnet are separated by domain walls in which 
the magnetization rotates from one direction to another. Magnetic behavior of bulk 
ferromagnetic materials is governed by the dynamics of these domains. Unlike the paramagnets, 
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ferromagnets will not relax back to zero magnetization upon removal of the external magnetic 
field since the domain wall motion process is not reversible which is known as “hysteresis”. One 
characterizes this M-H curve using three parameters; the saturation magnetization (Ms), the 
coercivity (Hc) and the remnant magnetization (Mr) (Figure 2.2). 
 
Figure 2.2: M-H curve for a collection of ferromagnetic particles showing hysteresis 
2.2: Magnetic nanoparticles and superparamagnetism 
 As mentioned in chapter 1, magnetic nanoparticles refer to materials with size ranging 
from few nanometers to several hundred nanometers which are ferromagnetic or ferrimagnetic in 
its solid bulk form. As the particle size decreases below a critical value, the formation of domain 
walls become energetically unfavorable and particles become single domain particles in which 
all the spins are aligned, called “superspins” with a large magnetic moment (~ 10,000 Bohr 
Magneton) on each particle. At temperatures above a characteristic temperature, TB, called 
Blocking temperature (described in Section 2.2.1), the moments on individual nanoparticles will 
tend to align an external applied field, similar to a paramagnetic material, but with a large 
magnetization. Figure 2.3 shows magnetic behavior of a collection of such nanoparticles under 
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an external magnetic field, without any hysteresis. This phenomenon is called 
“superparamagnetism” and is important to understand the magnetic behavior of nanoparticles. 
 
 
Figure 2.3: M-H curve for a collection of superparamagnetic nanoparticles 
For an assembly of non-interacting superparamagnetic particles, the magnetization (M) as a 
function of applied magnetic field (H) is explained by the Langevin function, 
𝐿(𝑥) = coth 𝑥 −
1
𝑥
                                                                         .2) 
where x=MsVH/kBT, Ms is the saturation magnetization and V is the volume of the particle given 
by V=πD3/6 in terms of diameter of the particle (D). When the particle size distribution is taken 
into account the magnetization can be written as, 





0
0
)(
)()(
)(
VdDDf
dDxVLDf
MHM s                                       (2.3) 
where f(D) if the log-normal distribution  given by, 
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Here, Do is the most probable particle diameter and σ is the width of the distribution. 
2.2.1: Magnetic Anisotropy in Nanoparticles 
 The magnetic properties of an ensemble of single domain particles are determined by the 
thermal energy and the magnetic anisotropy of the particle. In bulk magnetic materials, usually 
there is an energetically favorable direction along which the magnetic moments are typically 
aligned, referred to as the easy axis. The difference in magnetic energy to produce saturation in a 
hard direction is called the anisotropy energy. The most common types of anisotropy that affects 
the magnetic behavior of the material are magnetocrystalline anisotropy, surface anisotropy, 
shape anisotropy, exchange anisotropy, and induced anisotropy (for example, by stress) [110]. In 
nanoparticles, shape, surface and magneto crystalline anisotropies are the most important. Shape 
anisotropy arises from the long range dipolar interactions within the particle and causes 
magnetization to depend on the shape of the sample. For an example, in long thin needle shaped 
particles, it is easier to magnetize along its long axis compared with that along any of its short 
axes. A perfectly spherical nanoparticle having symmetry along all possible directions will have 
no shape anisotropy. As the size of the nanoparticle decreases, the surface to the volume ratio is 
increased and the surface effects become more significant. Therefore surface magnetic 
anisotropy is expected to contribute to the total magnetic anisotropy and the effective anisotropy 
is given by the following expression [111]; 
𝐾 = 𝐾𝑉 +
6𝐾𝑆 
𝐷
                                                                  (2.5) 
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Where, KV is the magnetocystalline anisotropy constant of the core, KS is the surface anisotropy 
energy constant, and D is the size of spherical particles.  
 Magnetocrystalline anisotropy arises from the symmetry of the lattice, the shape of the 
electron orbitals and from spin-orbit coupling. The actual direction of the magnetization can be 
either of two opposite directions along the easy axis. More precisely, this represents “uniaxial 
anisotropy”, but this is normally sufficient for understanding the magnetic response of 
nanoparticles. The magneto-crystalline anisotropy (E) is given by, 
 
2KVSinE        (2.6) 
where, K is the uniaxial anisotropy energy density and V is the volume of the particle and  is the 
angle between the magnetization and the easy axis. As the particle size is reduced, the anisotropy 
energy decreases. In sufficiently small particles, thermal energy KBT is comparable or larger than 
the anisotropy energy. If the thermal energy KBT is large compared to the anisotropy energy, the 
direction of the nanoparticle moment can flip freely between the two directions defined by the 
easy axis. Magnetic moments are randomly oriented leading to a zero net magnetization 
behaving as a superparamagnetic system. The relaxation time (), which is the average time it 
takes the magnetic moment to jump from one minimum to the other is given by the Neel-Brown 
relation: 







Tk
KV
B
exp0       (2.7) 
In this equation, τ0is a microscopic time scale for the transitions, which are typically taken to be 
10
-9
-10
-13
 s, kB is the Boltzmann’s constant and T is the temperature. As the thermal energy of the 
particle is reduced by lowering the temperature, the fluctuations slow down and the relaxation 
time increases. 
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Figure 2.4: (a) Energy barrier between two easy axes in a magnetic nanoparticle (b) (i) at 
temperatures below the TB of the particles, the net moments are quasi-static. (b) (ii). At 
temperature well above TB, the moment reversals are so rapid that the net magnetic 
moment is zero [112]. 
 The critical temperature, at which the relaxation time matches with the experimental 
measuring time,τ, is known as the blocking temperature (TB) and is a characteristic of the particle. 
The value of τm is given by the type of the measurement being performed. It is typically of the 
order of 10
2
 seconds for DC measurements and 10
-110-5s for AC susceptibility measurements. 
At the blocking temperature,  
𝑇𝐵  ≈ 𝐾𝑉 𝑘𝐵 𝑙𝑛(𝜏𝑚 𝜏0⁄ )⁄                                                            (2.8) 
Below this blocking temperature the spins are frozen over the timescale of each measurement. 
Above the blocking temperature, the moments possess enough energy to flip and particles 
behave   like simple paramagnets. The above ideas are illustrated in Figure 2.4. By measuring the 
temperature dependent DC magnetization of the material, the TB can be estimated to determine 
the magnetic anisotropy constant, K. 
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2.3: Magnetic dipolar interactions 
Magnetic dipole interaction between two magnetic dipoles µ1⃗⃗⃗⃗  and µ2⃗⃗⃗⃗ separated by a 
distance 𝑟  is described as, 
Ed   = 
µ0
4πr3
[µ
1
⃗⃗  ⃗. µ
2
⃗⃗  ⃗-
3
2 
(µ
1
⃗⃗  ⃗.r )(µ
2
⃗⃗  ⃗.r )]    (2.9) 
where μ0 is the permeability of free space. The atoms in a crystal have magnetic moment of a 
few Bohr magnetons. Therefore magnetic dipole interactions between atoms are very small and 
have a negligible influence on the magnetic ordering at finite temperatures compared to 
exchange interactions which are responsible for magnetic ordering in materials. However, 
ferromagnetic/ferrimaagnetic nanoparticles with dimensions around 10 nm can have magnetic 
moments as large as 10,000 Bohr magnetons, and therefore, dipole interactions between 
nanoparticles can have a significant influence on the magnetic properties. In a sample of 
randomly distributed nanoparticles having an average magnetic moment μ the dipole interaction 
energy of a particle can be written as, Ed≈
µ0µ
2
4πr3
 [113] .  
Over the past years, there are many studies that report the effect of dipolar interactions on 
the magnetic properties of nanoparticles. For example, Vargas et al [114]investigated the effect 
of dipolar interactions on magnetic properties of Fe based nanoparticles by tuning the strength of 
interactions by changing the concentrations of the particles. It is clearly shown that for increasing 
the particle concentration, the maximum of the ZFC curve shift to higher temperatures, 
indicating an increase in the blocking temperature, TB. A similar trend has been observed in many 
reported studies [115,116]. Dormann et al [115], analyzed the frequency dependence of the 
blocking temperature for a series of ɤ-Fe2O3 nanoparticles with different strengths of inter-
particle interactions.  He suggests that interparticle interactions simply lead to a progressive 
increase of the energy barrier. The model suggested by Dormann is based on a statistical 
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calculation of the dipolar energy for a collection of disordered particles with a non-zero size 
distribution and easy directions in random orientation. The interparticle interactions are 
described by an energy term, Eint with uniaxial symmetry hence added to the anisotropy energy 
for the particle alone. This leads to an increase in magnetocrystalline energy barrier, EB, and the 
modified relaxation time is given by, 
τ𝑁=τ0 exp [
EB+Eint
KBT
]                                                        (2.10) 
This model has been used to explain the similar results observed in other studies such as Fe 
particles embedded in an alumina matrix [117], γ-Fe2O3 particles dispersed in a polymer [116], 
magnetite particles dispersed in  dispersed in calcium silicate glasses [118] and as well as Ni NPs 
embedded in an amorphous SiO2/Cmatrix [119].The same observation, the increased relaxation 
time with increasing dipolar interactions, is explained by different approach in the study reported 
by Landi et al. [120].He defines an effective energy barrier based on a random mean field 
approximation. The dipolar interactions produced by an ensemble of particles are interpreted as 
random field acting on a reference particle resulting in a new term in the free energy of the 
reference particle, expressed as a cumulant expansion of the random field, carried up to fourth-
order. In this model, the dipolar interactions increase the effective anisotropy barrier rather than 
inciting some degree of order into the system. 
In addition to above models, there are other studies that employ Langevin function for 
better understanding of the role of dipolar interactions on the magnetic properties of 
nanoparticles.  This theory, known as T
*
 model, is proposed by Allia et al. [121] in his study on 
Granular Cu-Co alloys. He considers the particle moments to be interacting through long range 
dipolar random forces and pictures the effects in terms of a temperature T
*
 added to the actual 
temperature T in the denominator of the Langevin function argument which explains all features 
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of the experimental M(H) curves. His argument is justified as follows; the direction, sign, and 
magnitude of the dipolar field acting on any magnetic moment randomly changes at a 
sufficiently high rate which enhance the disorder of magnetic moments. This exerted disorder 
opposes the ordering effect of the external magnetic field which is similar to the role played by 
the temperature and hence strengthens its effects. The apparent temperature is written as 
Ta=T+T
*
, T
*
 is not an arbitrary quantity, but is related to the rms dipolar energy D through the 
relation, *kTD  .The experimental magnetization M, with modified Langevin function can now 
be written as, 
     
 
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By fitting the experimental magnetization data to the above expression, an estimation of the 
strength of dipolar interaction can be obtained. Even though this model explains the complex, 
collective effects of dipolar interactions in a simplified, but effective way, this has some limits 
which are addressed as well by the authors. Firstly, the ‘‘interaction’’ temperature T* may be 
much higher, larger than the measurement temperature. According to the authors, the T* 
obtained by best-fit procedure reflects not only changes in the spatial distribution of particles or 
in their degree of correlation, but also the presence of additional interactions among particles 
such as indirect interactions of RKKY type which are presence in metallic granular systems. 
When T increases towards Tc, T* drops, vanishing when T=Tc. On cooling, the T* becomes 
stronger, to finally become dominant without changing the functional form of the M (H) curve. 
When the temperature is lowered towards the blocked regime, the moments are expected to be 
frozen in random directions. Therefore, the argument of dynamic disorder provided by 
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interactions is no longer valid in the blocked regime. But as long as the measurements are taken 
at superparamagnetic regime, this model provides adequate understanding of the effects of 
dipolar interactions. 
2.4. Magnetic hyperthermia and linear response theory 
 The cyclic increase of internal energy of a magnetic system in adiabatic process is equal 
to the magnetic work done on the system and can be expressed as [122]: 
∆𝑈 = −𝜇0 ∮𝑀𝑑𝐻                                                .12) 
where M is the magnetization and µ0 is the permeability of free space and H is magnetic field 
intensity. The power dissipation in the magnetic system during several cycles is equal to the 
internal energy multiplied by the frequency, 𝑃 = 𝑈𝑓. As described by Rosensweig [122], the 
response of a magnetic system to an alternating external applied magnetic field , H(t) =H0cos(ωt), 
where ω is the angular frequency and H0 is the amplitude of the field, can be explained as follows. 
The magnetic susceptibility, χac, which describes the full dynamic response of a system to an external 
stimulus, can be written in terms of real and imaginary parts, 
    χ𝑎𝑐 = χ
′ − 𝑖χ′′     (2.13) 
Therefore, the resulting magnetization, M (t) is, 
M(t) = Re(χ𝑎𝑐𝐻0𝑒
𝑖𝜔𝑡) = 𝐻0(χ
′ cos𝜔𝑡 + χ′′ sin𝜔𝑡)  (2.14) 
Substituting M and H in Eq.1.14 yields, 
      ∆𝑈 = 2𝜇0𝐻0
2χ′′ ∫ 𝑠𝑖𝑛2 𝜔𝑡 𝑑𝑡
2𝜋
𝜔
0
     (2.15) 
Integrating the above equation and multiplying the result by the cyclic frequency f =ω/2π gives 
the power dissipation,   
𝑃 = 𝜇0𝜋χ
′′𝑓𝐻0
2     (2.16) 
The frequency dependence of the complex susceptibility is given by the following expression. 
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χ =
χ0
1+𝑖𝜔𝜏
                                            (2.17) 
The real and imaginary parts of the susceptibility can therefore be expressed as: 
χ′ =
χ0
1+(𝜔𝜏)2
      (2.18) 
χ′′ =
𝜔𝜏
1+(𝜔𝜏)2
 χ0     (2.19) 
Here  χ0 is the equilibrium susceptibility, which is expressed as, 






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
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1
coth0 i               (2.20) 
where χi = (µ0ΦMd
2 
Vm)/3kBT,initial susceptibility , ξ = (µ0 MdH0Vm)/kBT with Md, the domain 
magnetization of the nanoparticle, and Φ is the volume fraction of the magnetic nanoparticles in 
the ferrofluid. Under the influence of an external alternating magnetic field, nanoparticles generate 
heat due to relaxation losses (Neel and Brownian relaxations) and hysteresis losses. In 
superparamagnetic particles, with negligible /zero coercivity, the contribution from the latter is not 
significant at all and the relaxation losses are the prominent mechanisms. The relaxation mechanisms 
are illustrated in Figure 2.5. 
 
Figure 2.5: Left: Neel relaxation showing the rotation of magnetic moment (white 
arrow). Right: Brownian relaxation where the physical rotation of the nanoparticle takes 
place to align the moments along the magnetic field [36]. 
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In case of the Brownian relaxation, heating of the particles in liquid suspension occurs 
due to viscous drag between the particles and liquid, where the entire particle physically rotate to 
align the magnetic moment with the applied field. The Brownian relaxation time is given by the 
equation 2.22, 
Tk
R
B
H
B
34
        (2.21) 
Here  is the viscosity of the suspension and RH is the hydrodynamic radius of the surfactant 
coated nanoparticle. For Neel relaxation, the moments of the particles fluctuate with the applied 
field and the relaxation time is given by the following equation. 
Tk
KV
Tk
KV
BB
N 


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
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 exp
2
0

     (2.22) 
Since the Brownian and Neel processes take place in parallel, the combined relaxation of the 
particle is characterized by the effective relaxation time eff  ,defined as: 1/eff =(1/1/
By substituting the Eq 2.19 in the  power dissipation expression given by Eq. 2.16, and taking 
the polydispersity of the particles into account by incorporating the log normal distribution given 
by Eq.2.4,  the temperature dependent power dissipation in the sample can be expressed as, 
 



0
2
2
000 )()(
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                              (2.23) 
Depending on the value of ωτ , two regime can be identified;  the high frequency limit in which 
𝜔𝜏 ≫ 1 and the low frequency limit where 𝜔𝜏 ≪ 1.In high frequency limit Eq 2.24 reduces 
to the following expression which clearly shows that at higher frequencies the generated 
power is independent of the frequency ω. 
𝑃 = 𝜇0𝐻0
2χ 
1
2𝜏
                                                                     .24) 
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On the other hand, in the low frequency limit where ωτ<< 1, the power is proportional to the 
square of the frequency as shown below. 
𝑃 = 𝜇0𝐻0
2χ 
𝜔2𝜏
2
                                                                 (2.25) 
The linear response theory described above assumes the magnetic response of the system to be 
linear with the applied magnetic field. To be more specific this theory is valid in the 
superparamagnetic regime where 𝐻0 < 𝑘𝐵𝑇 𝜇0𝑀𝑠𝑉⁄ . 
Finally, in order to incorporate the dipolar interactions in this model, we replaced the 
temperature term T in in the above equations with the apparent temperature (T+T*), as done in the 
analysis of M-H data using Langevin model.  
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CHAPTER 3 SYNTHESIS AND CHARACTERIZATION 
METHODS OF MAGNETIC NANOPARTICLES 
3.1: Synthesis of Fe3O4 nanoparticles 
Over the past years many research works have been done to develop efficient synthesis 
approaches to produce the size/shape controlled, stable, biocompatible, and monodispersed iron 
oxide nanoparticles (NPs) [123-126]. The most common methods include co-precipitation 
[51,127], thermal decomposition [128], hydrothermal synthesis [129,130], microemulsion [131] 
and sonochemical [106] synthesis. The most conventional method for obtaining Fe3O4 or ɤ-
Fe2O3 is by co-precipitation which consists of mixing ferric and ferrous salts in highly basic 
solutions at room temperature or at elevated temperature. The size and shape of the iron oxide 
nanoparticles depends on the type and amount of salt used (Fe
2+
:Fe
3+ 
ratio), the reaction 
temperature, the pH value, ionic strength of the media, and the other reaction parameters such as 
stirring rate, dropping speed of basic solution. Co-precipitation method results in the production 
of water-soluble magnetic nanoparticles and is relatively cost-effective compared to other 
synthesis techniques. However, this method leads to nanoparticles with wide particle size 
distribution due to lack of control over hydrolysis reactions of the iron precursors and the 
nucleation and growth steps causing a wide range of their blocking temperatures. Thermal 
decomposition technique, decomposition of organo-metallic iron precursors at higher 
temperatures in organic solvents, involves complicated operation and generates high quality 
monodisperse particles because of separate nucleation and growth processes. But the resulting 
nanoparticles are hydrophobic and thus cannot be directly used for bio-applications. In order to 
make them water soluble, laborious post-synthesis ligand exchange procedures are necessary, 
which may result in aggregation and loss of magnetic properties. The other common, recently 
developed, method is hydrothermal synthesis which generates nanoparticles with excellent 
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crystallinity with controllable size and shape in aqueous phase. The properties of the 
nanoparticles can vary with the synthesis method due to the differences in cationic distribution 
and vacancies, spin canting, or surface contribution. 
For the synthesis of nanoparticles studied in this thesis work, chemical co-precipitation 
and hydrothermal method were used as standard methods of synthesis because of the simplicity, 
and ability to produce superparamagnetic iron oxide nanoparticles of reasonable size (10-15 nm). 
Moreover, these techniques are compatible with different approaches we are using for 
functionalizing the nanoparticles. 
3.1.1: Co-precipitation synthesis 
 The reagent precursor chemicals, FeCl24H2O and FeCl36H2O were obtained from 
Merck and were used without further purification. Aqueous solutions of FeCl2.4H2O and 
FeCl3.6H2O were mixed in 1:2 molar ratios. For a typical synthesis, 5.4 g of FeCl3.6H2O in 20 
mL of 2 M HCl was mixed with 2.0 g of FeCl2.4H2O in 5 mL of 2 M HCl in a 1 L beaker. After 
stirring the mixture with magnetic stirrer for about 5 min, 250 mL of 1 M NH4OH was added 
dropwise into the mixture under constant magnetic stirring, which resulted in a brown precipitate 
that became black eventually upon the formation of Fe3O4 nanoparticles (Figure 3.1).  
 
 
   
 
Figure 3.1: Synthesis of Fe3O4 nanoparticles by chemical co-precipitation technique. 
The chemical reaction may be written as follows; 
NH4OH  
Fe
3+ 
/Fe
2+ 
solution 
Washed  x10 
28 
 
 
𝐹𝑒2+  + 2𝐹𝑒3+ + 8OH− → 𝐹𝑒3𝑂4 + 4𝐻2𝑂 + 8𝐻𝐶𝑙 
The nanoparticles were stirred for another 10 minutes, isolated with a magnet and washed 
several times with deionized water until a neutral pH was reached which was confirmed by a 
litmus paper.  
The particle size of the nanoparticles obtained from the co-precipitation method can be 
varied in the range of 6-13 nm by changing the different experimental parameters such as the 
RPM rate, rate of adding the base to the reaction mixture, concentrations of the salts and the base 
etc. For example, using 2 M NH4OH added rapidly to the reaction mixture under 1000 rpm of 
stirring rate resulted in generating nanoparticles of 6-7 nm size whereas using 1 M NH4OH 
added dropwise to the reaction mixture under a stirring rate of 350rpm  produces 11-12 sized 
nanoparticles.  
3.1.2: Hydrothermal synthesis 
 The Hydrothermal synthesis of Fe3O4 nanoparticles was carried out by precipitating 
FeCl2.4H2O and FeCl3.6H2O (1:2 molar ratio) in alkaline medium (NH4OH) followed by the 
hydrothermal treatment. 2.0 g of FeCl2.4H2O and 5.4 g of FeCl3.6H2O were mixed in 50 ml of 
2M HCl solution 10 ml of NH4OH solution was then added dropwise into the mixture under 
constant magnetic stirring. After 10 minutes of stirring, the mixture, which contains the 
precipitated black product, was immediately added into a Teflon-lined stainless steel autoclave 
with 60 ml capacity and subsequently placed in a furnace at 134 °C for 1 h. The autoclave was 
cooled naturally after the hydrothermal treatment and the precipitate was recovered and washed 
several times with DI water by means of a magnet. 
After the synthesis of the nanoparticles they were washed to remove the excess ions 
which resulted in wet slurry. Several portions of the slurry were then used to quantify the amount 
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of iron oxide in each gram of the slurry. This estimation was used to determine the concentration 
of the prepared ferrofluid. This method of calibration at the beginning of the preparation of the 
ferrofluid, provides an accurate method of reporting the concentration of the ferrofluid with a 
narrow window of uncertainty. 
3.2:  Surface functionalization of Fe3O4 nanoparticles 
 In our research, we used dextran, a natural polysaccharide, and citric acid for the 
preparation of ferrofluid. Both the materials have different moieties which allow us the further 
functionalization with anti-cancer drugs, dyes and targeting ligands. Dextran has the hydroxyl 
groups which could be attached to the amine group or concerted into carboxyl groups whereas 
citric acid contains carboxyl groups providing many possibilities of functionalization.  
3.2.1: Dextran coated Fe3O4 nanoparticles 
 In order to coat the Fe3O4 nanoparticles with dextran, synthesized nanoparticles (from the 
wet slurry)and 60-90 kDa dextran (1:1 wt.) were dispersed in 25 ml of 0.5 M NaOH separately. 
The dextran solution was kept under sonicating and the iron oxide nanoparticles solution was 
added drop wise into the dextran solution over 30 minutes period. The resulting mixture was 
sonicated for 24 hours to get the well suspended ferrofluid which was stable over 6 month’s 
period. 
3.2.2: Citric acid (CA) coated Fe3O4 nanoparticles 
Citric acid stabilized nanoparticles were prepared by direct addition method [132]. 
Simply, 5ml of 0.1mg/ml citric acid solution was added to 0.5g of Fe3O4 nanoparticles dispersed 
in 20ml of 0.5 M NaOH solution. The mixture was heated to 90 ºC and stirred for 60 minutes. 
After that the solution was cooled down to room temperature and was dialyzed using 8-10 kDa 
cutoff membrane to remove excess citric acid. 
30 
 
 
3.2.3:Cross-linking of Fe3O4 nanoparticles 
Cross-linking of Dextran coated Fe3O4 nanoparticles, which endows a greater stability  of 
nanoparticles, was carried out using an established published procedure [80]. Dextran coated 
Fe3O4 were cross-linked using epichlorohydrin (ECH). The solution containing 1 ml of dextran 
coated Fe3O4 nanoparticles; 5 ml of 5 M NaOH, 2 ml of DI water and 2 ml of ECH was 
prepared. The mixture was incubated at room temperature with continuous shaking to promote 
the interaction between aqueous and organic phase. After 24 hours of incubation, the black 
colloidal suspension was dialyzed several times against DI water to remove the excessive ECH 
and ions.  
3.2.4: FITC functionalized Fe3O4 nanoparticles 
 Fluoro isothiocyanate (FITC) is a widely used fluorescent dye, frequently used for 
cellular imaging. The functional group of FITC, isothiocyanate group, is reactive towards amine 
group which makes it possible for conjugation. To graft the surface of Fe3O4nanoparticles with 
required amine group, 1.25 ml of concentrated NH4OH was added to the cross linked Fe3O4 
nanoparticles solution and the mixture was left for continuous sonication overnight. To label 
dextran coated Fe3O4 with FITC, 1 ml of 0.01 M FITC (10 μmol) in phosphate buffer saline 
(PBS) at pH 7.4 was added to 1 ml of amino functionalized cross linked Fe3O4. The mixture was 
allowed to stand for 1 hour at room temperature and excess FITC was removed by dialysis. 
3.3: Cell culture protocol 
All the in-vitro cell studies done in this research were conducted on human pancreatic 
cancer cells, Mia PaCa 2.The cell culture experiments were carried out inside a cell culture hood. 
 MIA PaCa-2 human pancreatic cancer cells were cultured on poly L-lysine-coated petri 
dishes in Cell Growth Medium (CGM) made of Dulbecco’s modified essential medium (DMEM) 
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containing 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin. To continue the cell 
line, the confluent plate is split and cells are re-cultured on a new plate as described below. Cell 
culture plate which was stored in the incubator was taken out and growth media was carefully 
aspirated. The cells were washed twice with 10 ml of sterile 1X phosphate buffered saline (PBS) 
at pH 7.4 followed by exposure to 0.25% trypsin in PBS for 3-4 minutes inside the incubator 
which detaches the cells from the surface of the plate. CGM was then added to terminate the 
trypsin activity. The resulting cell suspension was centrifuged for 4 minutes at 1,500 rpm (300g), 
and the pellet re-suspended in 6 ml of cell growth medium. Then 1 ml of this suspension was 
added to a new culture plate containing 9 ml of fresh CGM. To keep the cells healthy splitting 
was done twice a week. 
3.4: Structural characterization methods 
In order to confirm that the synthesized samples have the required properties for intended 
applications we have utilized different characterization techniques as described in the rest of the 
chapter. X-ray diffraction is mainly and commonly used to identify the crystal structure of the 
material, to estimate the crystalline size and to identify the crystalline impurities in the sample 
whereas transmission electron microscopy is a great tool to investigate the morphology and 
determine the particle size distribution accurately. Colloidal parameters such as hydrodynamic 
size and zeta potential are determined using dynamic light scattering. 
3.4.1: X-ray diffraction (XRD) 
 X-rays are electromagnetic radiation with the wavelength of 0.01 to 10 nm corresponding 
to energies in the range of 100 eV to 100 keV. X-rays with short wavelengths that are 
comparable to the size of atoms can be used to probe the arrangement of atoms and molecules 
inside the crystalline materials. Generally, Cu and Mo targets are used in diffractometers which 
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produce x- rays of wavelength 1.54 Å and 0.8 Å respectively. When x-rays interact with atoms 
of the materials, waves diffracted from different layers of atoms interfere with one other to 
produce sharp maxima in the intensity (constructive interference) if atoms are arranged 
periodically (Figure 3.2).The basic principle of XRD is described by Bragg’s Law, 
2𝑑(ℎ𝑘𝑙) sin 𝜃 = 𝑛𝜆                                                          (3.1) 
where, d (hkl) is the spacing between the atomic planes with the Miller indices hkl, θ is the angle 
between the incident rays and the atomic planes, n is any positive integer and λ is the wavelength 
of the incident rays. 
 
Figure 3.2: The diffraction of x-rays from atomic planes 
A typical powder x-ray diffractometer consists of an x-ray source, a sample stage, a 
detector. The x-ray is focused on the sample at an angle θ, while the detector opposite the source 
reads the intensity of the x-ray it receives at 2θ away from the source path (Figure 3.3). The 
incident angle is increased over time always keeping the detector angle 2θ above the source path. 
For our XRD measurements nanoparticle powder samples, we used a Rigaku MiniFlex 600 X-
ray diffractometer with a θ-2θ scanning mode operating at a voltage of 40 kV and current of 150 
mA. The average crystalline size of the particles, davg, can be estimated by the Debye-Scherrer 
equation, 
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𝑑𝑎𝑣𝑔 =
𝑘𝜆
𝛽𝐹𝑊𝐻𝑀 cos𝜃
      (3.2) 
where, λ is the x-ray wavelength, k is the shape factor which is roughly equal to 0.94 for 
spherical particles, βFWHM is the full width at half mamixa measured in radians and θ is the 
diffraction angle. 
 
Figure 3.3: The powder x-ray diffractometer geometry 
3.4.2: Transmission electron microcopy (TEM) 
 TEM is a powerful imaging tool used in medical, biological, and materials research. The 
basic principle of operation is similar to that of optical microscope, the difference being that 
TEM uses electrons instead of light. The wavelength of the electrons is much smaller (in the 
order of 10 to 100 pm) than the wavelength of light hence its resolution is many orders of 
magnitudes higher than an optical microscope which allow us to “see” the particles sized in nano 
range. The electrons that are emitted from an electron gun at the top of the microscope travel 
through the vacuum in the column of the microscope. This traveling electron beam is focused 
into very thin beams by means of electromagnetic lenses and the concentrated beam is then 
incident on the thin sample specimen of interest. These electrons are absorbed, scattered and 
transmitted through the sample. Transmitted electrons strike the fluorescent or photographic 
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screen at the bottom of the microscope generating a shadow image of the specimen which is 
visualized by means of a sophisticated camera. These images contain useful information about 
the morphology and crystal structure of the sample. A JEOL 2010 FasTEM transmission electron 
microscope operated at 200 kV was used to obtain the TEM images of our nanoparticles. The 
sample preparation for TEM was done by mounting one or two drops of diluted solution of 
nanoparticles dispersed in ethanol on a carbon coated copper grid followed by drying. 
3.4.3: Dynamic light scattering (DLS) 
Dynamic light scattering and photon correlation spectroscopy are widely used to 
determine the hydrodynamic size and size distribution of colloidal particles. When a 
monochromatic beam of light, such as laser, passes through a solution, time dependent 
fluctuations in the intensity of scattered light occur due to the Brownian motion of the particles 
in the solution. An autocorrelation analysis of these intensity fluctuations provides an estimation 
of the diffusion coefficient (D) which relates to the hydrodynamic size or diameter, dH, The 
autocorrelation function is given by a single exponential function, where A is the baseline at 
infinite decay and β is the amplitude at zero decay. 
  𝐶(𝜏) = 𝐴 + 𝛽𝑒𝑥𝑝(−2𝜏Γ)     (3.3) 
The above equation can be used to determine Γ which relates to the diffusion constant D 
through  𝐷 = Γ 𝑞2⁄  where q is the scattering wave vector, a quantity that is related to the 
scattering angle, wave length of the laser and the refractive index of the solution. The 
hrdrodynamic size or diameter, dH , can be then estimated using Stokes-Einstein relation (Eq 
3.4), 
𝐷 =
𝑘𝐵𝑇
6𝜋𝜂d𝐻
       (3.4) 
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η, kB,T being the viscosity of the medium, boltzman constant and absolute temperature 
respectively. 
Both the hydrodynamic size distribution and zeta potential measurements (described in 
the next section) were done using a Nano ZS90 (Malvern Instruments). Ferrofluids were diluted 
using DI water and the pH of the dilute solution was measured using pH meter. The 
concentration of the nanoparticle dispersions used for these measurements was kept in the range 
of 50-100 µg/ml. 
3.4.4:  Zeta potential measurements 
 The particles in a colloidal suspension carry an electrical charge and the amount of 
charge on the particle surface is an important characteristic which determines stability of the 
particles in a suspension. This surface charge creates a countercharge in the surrounding solution 
screening the electric surface charge forming an electrical double layer. The magnitude of the net 
electric charge in this screening diffused layer is equal that of net surface charge, but has the 
opposite polarity. As a result the overall structure is electrically neutral. The charges on the 
particle surface are normally considered to be attached rather firmly and the outer boundary of 
this layer is defined as the Stern layer. The surrounding charge, by contrast, is much more 
loosely associated with the particle and diffuses with the charged particle. The boundary of this 
layer is defined as the slipping plane (Fig. 3.4). The electrostatic potential changes very quickly 
(and linearly) through the surface- layer whereas it changes more or less exponentially through 
the diffuse layer. The charge or electrostatic potential at the slipping plane is defined as the zeta 
potential (ξ) and is the key indicator of the stability of colloidal suspensions. It depends on the 
properties of the dispersive medium such as pH as well as on properties of the surface. 
36 
 
 
Electrostatic repulsion between particles depends on the value of zeta potential hence higher the 
absolute value of the zeta potential would lead to a more stable the system. 
 
Figure 3.4: Distribution of charges around a charged particle in a colloidal suspension 
3.5: Magnetic characterization 
 The magnetic properties (saturation magnetization, magnetic core radius, coercivity, etc.) 
of the synthesized powder as well as the ferrofluid samples were determined using a Quantum 
Design Model 6000 Physical Property Measurement System (PPMS). It can be used to take 
measurements in the temperature range from 1.8 to 400 K with magnetic fields up to 9 T. The 
PPMS consists of a cryostat unit having superconducting magnetic coil. The sensitivity of AC 
and DC measurements are 10
-8
 and 10
-5
 emu, respectively. Sample preparation for the 
measurements of powder samples was done as follows: Approximately, 20-30 mg of 
nanoparticles was placed in a gelatin capsule, packed with cotton to restrict the motion of the 
sample and mounted in a straw with proper stitching. For the ferrofuid samples, we used a sealed 
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liquid sample holder purchased from Quantum Design. However using this holder limits our 
ferrofluid measurements at 300 K. 
 In order to investigate the dynamic relaxation of the synthesized particles, AC 
magnetization measurements on the powder samples under a 10 Oe excitation were taken in the 
entire temperature range T = 10 K to 300 K using PPMS .The measurements were done at 
different frequencies ranging from 350 Hz to 2000 Hz. 
3.6: Magnetic hyperthermia measurements 
The schematic of experimental set up for a typical hyperthermia set up (Fig. 3.5.a) consist 
of a parallel LC tank circuit. The coil carrying the current provided by the amplifier essentially 
acts as an inductor of inductance L. It is connected to a capacitor of capacitance C and this 
arrangement generates and oscillating magnetic field of a particular frequency. The ferrofluid 
sample is positioned inside the coil with an insulation cover to prevent heat exchange with the 
surroundings (adiabatic system). For the magnetic hyperthermia measurements, we used an 
Ambrell Easy heat station coupled with a solenoid (Fig. 3.5.b).  
 
 
Figure 3.5: (a) The experimental set up for a typical hyperthermia set up (b) Ambrell 
Easy Heat System and OPTOCON fiber optic thermometer. The coil, sample holder and 
insulating cotton padding are shown as well. 
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The temperature of the sample was measured using an Optocon P/N FOTEMP1-OEM fiber optic 
thermometer interfaced to the computer for automatic data collection every 2 or 5 seconds. The 
current passing through the circuit gives estimation on the amplitude of the magnetic field while 
the values of L and C determine the magnitude of the frequency. The higher SAR value can be 
achieved by increasing the amplitude (H) and frequency (f) of the applied field. But to prevent 
unwarranted side effects and nerve stimulation, magnitude and frequency need to be within 
safety limit set to H. f=5×10 
-9
 Am
-1
s
-1
. Therefore, all our measurements had been recorded under 
ac magnetic field amplitude of 235 Oe and at a frequency of 375 kHz which are within the 
required limit.   
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CHAPTER 4 EFFECT OF MAGNETIC DIPOLAR 
INTERACTIONS ON TEMPERATURE DEPENDENT 
MAGNETIC HYPERTHERMIA IN Fe3O4 FERROFLUIDS  
4.1: Introduction 
As described in the earlier chapters, superparamagnetic Fe3O4 nanoparticles have 
attracted a great deal of attention because of their potential applications in biomedicine and 
Magnetic hyperthermia (MHT) is one of the extensively studied applications. In MHT an 
external alternating magnetic field is applied to a tissue containing MNPs, which serve as the 
heat centers producing heat by relaxation losses thereby heating the tissue. As the MHT can be 
used for heating small regions selectively, it offers the potential for being highly selective and 
non-invasive technique for therapeutic treatment of cancers and as a consequence it has 
advantage over other treatment methods such as chemotherapy and radiation therapy. 
 Specific absorption rate (SAR), which measures the efficiency of heat generation, 
depends on magnetic properties of the particles such as saturation magnetization, magnetic 
anisotropy, particle size distribution, magnetic dipolar interactions, and the rheological properties 
of the target medium. Therefore, the applications of the Fe3O4 nanoparticles often require 
controllable synthesis methods to produce particles with desired size, shape and magnetic 
properties. Different synthesis methods often yield systems consisting of polydisperse ensemble 
of MNPs of different sizes as seen in transmission electron microscopy (TEM) images, with size 
distribution usually describable by a log-normal distribution function. MHT investigations are 
often done on colloidal suspensions of MNPs, called ferrofluids, where the nanoparticles are 
coated with surfactants to avoid agglomeration and minimize the effects magnetic dipolar 
interactions. Some ferrofluid preparations yield a mixture of isolated nanoparticles and 
nanocluseters [133], with varying degree of magnetic dipole-dipole interactions present in 
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ferrofluids. It is shown that the dipolar interactions among the MNPs affects the SAR value 
drastically hence that can be exploited to optimize SAR [133-136]. For a nanoparticle system 
consisting of polydisperse particles, a phenomenological theory was proposed to take into 
account the effects of magnetic dipolar interactions resulting from the magnetic 
moments/superspins of the superparamgnetic nanoparticles [121]. In this, so called the T
*
 model, 
dipolar interaction is taken into account by replacing the temperature, T, appearing in the 
argument of the Langevin function, by T + T
*
, where T
*
 is a phenomenological parameter.  The 
model was used to explain all the features of the observed M vs. H curves in granular Cu-Co 
alloys.  Effects of dipolar interactions on SAR for a collection of monodisperse MNPs has been 
described Landi [120,135] by using mean-field approximation by modifying the relaxation time. 
As mentioned earlier, synthesis method is a key factor that determines the properties of the NPs. 
Over the years, many methods have been developed for synthesizing size/shape controlled, 
stable, biocompatible iron oxide nanoparticles as described in Chapter 3.  
 In this study, we have synthesized Fe3O4 nanoparticles using two different synthesis 
methods: co-precipitation (CP) and hydrothermal (HT) techniques, yielding very similar x-ray 
crystallite size ~ 12 nm, which were coated with dextran to obtain a well suspended, 
biocompatible ferrofluids.  We noted that both CP and HT prepared ferrofluids show very similar 
saturation magnetization ~ 70 emu/g and yet exhibit very different SAR values of ~ 110 Watt/g 
and 40 Watt/g, respectively, at room temperature. We explain this observed reduction in SAR 
value by taking into account the dipolar interactions, using the phenomenological T
*
 model 
(Chapter 2.3), to fit the observed M vs. H data using Langevin function, and the temperature 
dependent SAR data using linear response theory. The values of the magnetic anisotropy 
constant, obtained as a fitting parameter in the temperature dependent SAR calculations, are in 
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good agreement with the values determined by frequency dependent magnetic susceptibility vs. 
temperature data of powder samples.  
4.2: Experimental details  
 Preparation of the Fe3O4 nanoparticles by CP and HT method was done using procedure 
described in chapter 3. The synthesized nanoparticles were coated with dextran to obtain well 
suspended ferrofluid following the experimental procedure described in section 3.2.1. 
 The x-ray diffraction patterns of Fe3O4 nanoparticles (CP and HT) were measured with a 
Rigaku MiniFlex 600 x-ray diffractometer using CuKα radiation. Transmission electron 
microscopy images were obtained using a JEOL 2010 transmission electron microscope (TEM). 
The samples for TEM imaging were prepared by suspending the magnetic nanoparticles in water 
followed by sonication for several minutes and adding a drop of that solution onto a carbon-
coated TEM copper grid and subsequently drying in air. The magnetic properties of ferrofluid 
samples were investigated by measuring M vs. H curves at 300 K using a Physical Property 
Measurement System (PPMS). We also measured both frequency (350 Hz to 2000 Hz) and 
temperature dependent (10 K to 300 K) magnetic susceptibility curves of powder samples at a 
field amplitude of 10 Oe to investigate their blocking behavior. 
The magnetic hyperthermia measurements were carried out using an Ambrell Easy Heat 
system, which consists of a simple solenoid, a capacitor and a power amplifier as described in 
chapter 3. Small glass vials were used to hold the ferrofluid samples and the vials were padded 
with a cotton sleeve to minimize the heat loss to the surrounding. The magnetic hyperthermia 
measurements were made by applying an ac magnetic field of amplitude 240 Oe (19.1 kA/m) at 
375 kHz. The temperature of the sample was monitored using an Optocon P/N FOTEMP1-OEM 
fiber optic thermometer, which was inserted through a small hole at the center of the top cover of 
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the vial to make contact with the ferrofluid. The thermometer was connected to a computer and 
the heating curve (temperature vs time) readings were logged at a regular interval of 2 s. To 
account for the heat loss to the environment the cooling curves were recorded immediately after 
the magnetic field was turned off, as described elsewhere (chapter 3). 
4.3: Results and discussion 
The XRD patterns of the as-prepared CP and HT Fe3O4 nanoparticles are shown in Fig.4.1. 
 
Figure 4.1: X-ray diffraction patterns of as prepared Fe3O4 nanoparticles (a) by 
hydrothermal (HT), and (b) by co-precipitation (CP) methods. 
 All the observed peaks in the diffraction patterns are consistent with those of standard XRD 
pattern of Fe3O4 (reference JCPDS No. 82-1533) confirming cubic crystalline structure and the 
absence of any impurities within the XRD detection limits. The average crystallite size of the CP 
and HT samples using Debye-Scherer equation was determined to be 11.7±0.6 nm and 11.8±0.5 
nm. TEM images (Fig. 4.2) clearly show that the samples contain nearly spherical particles with 
a distributed particle sizes (polydispersed).  
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Figure 4.2: TEM images of the as prepared Fe3O4 nanoparticles prepared by (a) CP 
method, (b) HT method, and their histograms of the particle size distribution.  The solid 
lines in the histograms represent the log-normal fits. 
The particle size distributions of two samples were determined by measuring the sizes of 
at least 200 particles from the TEM images and fitting the histogram with a log-normal 
distribution function, Eq.2.4, 
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probable particle diameter and is the width of the distribution. The histogram and the log-
normal fits are shown in Fig. 4.2. Interestingly, the average particle sizes of the CP and HT 
nanoparticles are calculated to be 13.8±3.1 nm and 14.6±3.6 nm, which are slightly larger than 
their corresponding estimated XRD crystallite sizes. The previous studies done on Fe3O4 
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nanoparticles also have reported a larger TEM size than their XRD crystallite size  similar to this 
observation [133], and the observed difference is attributed to existence of an amorphous layer of 
1-2 nm thickness on the surface of the nanoparticles [137]. 
Figure 4.3 shows the field dependent DC magnetization, M(H),  curves of CP and HT 
prepared Fe3O4 nanoparticle ferrofluids at room temperature.  
 
Figure 4.3:   Room temperature M vs. H curves of the ferrofluid samples of Fe3O4 
nanoparticles prepared by CP and HT methods. The solid lines are the theoretical fits.  
 Both the systems show superparamagnetic behavior with zero coercivity and a very 
similar saturation magnetization of ~ 70 ± 2 emu/g. This value  is  lower than the value reported 
for bulk Fe3O4 ~ 92 emu/g,  which is attributed  to the surface disorder such as  the existence of 
magnetic dead layer, spin canting at the particle surface or the spin-glass like behavior of the 
surface spins modifying the anisotropy and the magnetic moments of the surface atoms 
[138,139]. It has also been shown in the literature that the saturation magnetization of the 
particles, in general, increases with the crystallite size [140]. The observation of similar value of 
saturation magnetization in our CP and HT samples is consistent with our XRD/TEM results 
showing similar crystallite/physical size.  
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However, the M (H) curves differ at lower fields (see Fig. 4.3), perhaps indicative of a 
difference in magnetic core size distribution. Assuming the superparamagnetic particles are non-
interacting, M-vs-H data can be fitted using Eq. 2.3, 
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Using the particle size (Do) and the width of the distribution () as fitting parameters, we 
found the best fitting yielded the average particle diameters to be 10.8±2.0 nm and 7.6±3.2 nm 
for CP sample and HT samples. However, these parameters are not consistent with the measured 
values from XRD analysis and in particularly, the deviation is significant for the HT sample. We 
attribute this discrepancy due to the presence of magnetic dipolar interactions among 
nanoparticles in the ferrofluid samples. We have accounted for the dipolar interactions by 
introduced a phenomenological temperature, T
*
, in the modified the Langevin function,
x
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s  as described in section 2.3. The solid lines in Fig. 3 
show the best fits for CP and HT ferrofluids using the modified Langevin function in Eq. (2), and 
using T* as an additional fitting parameter while constraining the average particle diameter close 
to their XRD crystallite size. Table 4.1 gives a summary of the fitting parameters.   
Table 4.1: Fitting parameters obtained from the Langevin fitting for CP and HT ferrofluid 
samples 
 
Sample D0 (nm) λ T
* 
(K) Davg (nm) 
CP-Ferrofluid 10.6 0.19 0 10.8 ± 2.1 
11.6 0.19 70 11.8 ± 2.3 
HT-Ferrofluid 7.0 0.40 0 7.6 ± 3.2 
10.9 0.35 550 11.6 ± 4.2 
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Clearly, the M (H) fitting shows the presence of dipolar interaction in both samples with 
interaction being much stronger in HT sample compared to the CP sample.   Nanoparticles in CP 
ferrofluid exhibit nearly non-interacting superparamgnetic behavior with a smaller T* ~ 75 K, 
corresponding to an interaction energy of ~ 6 meV. One would expect this as the nanoparticles 
are small and are coated with polymer surfactants which form a thick layer on the particles 
increasing the interparticle distance (hydrodynamic size ~ 100 nm) in ferrofluid, resulting in 
decreased dipolar interactions. On the other hand, HT sample shows an order magnitude higher 
T* value compared to the CP sample indicating the presence of strong dipolar interactions 
among nanoparticles in HT ferrofluid. We also notice that the polydispersity in the particle size 
is much broader in HT prepared samples. We believe that the HT method of synthesis which 
involves heating at 140 
o
C leads to particle agglomeration and an increased fraction of clustered 
nanoparticles in the surfactant coated ferrofluid particles. 
The results of magnetic hyperthermia measurements of CP and HT ferrofluid samples are 
shown in Fig. 4.4 with the inset showing the heating curves.  Specific absorption rate, (SAR), of 
the ferrofluid samples were determined according to, [122] 
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)(      (3)  
where, Msample  is the mass of the sample,  mFe3O4   is the mass of Fe3O4 nanoparticles in the 
sample, C is the specific heat capacity of the sample, and 
Tdt
dT






is the time rate of change of 
temperature at T. The details of the measurements of heating and cooling curves, and the 
analyses of data to extract the temperature dependant SAR by fitting the heating and cooling 
curves to obtain 





dt
dT
 as a function of temperature is reported in Nemala et al [137].  The heat 
47 
 
 
capacity of the sample was assumed to be close to that of the carrier liquid (water) due to low 
concentration of nanoparticles in the samples. Clearly, the SAR data of the two samples are 
strikingly different although they both have similar average particle size. As discussed below, we 
have used the linear response theory to fit the entire temperature dependent SAR using the T* 
model to take the dipolar interactions into account and investigate the effect of magnetic 
anisotropy as described below. 
For an ensemble of polydisperse particles, the temperature dependent average power 
dissipation in the sample isgiven by the Eq.4.3, 
 

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                                  (4.3) 
Here, Ho and ωare the amplitude and angular frequencyof the applied ac magnetic field, o is the 
vacuum permeability. eff   is effective relaxation time involving Néel relaxation, Brownian 
relaxation times and o is equilibrium susceptibility and defined as
BNeff 
111
 . When 
dipolar interactions are taken into account using T* model, the Néel and Brownian relaxation 
times can be modified as 
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these expressions, is the viscosity of the suspension and RH is thehydrodynamic radius of the 
coated nanoparticle, K is the anisotropy constant, Vm is the magnetic volume of the nanoparticles, 
τo ~ 10
-9
s and T is the sample temperature.o is given by 
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magnetization of the nanoparticle, and  is the volume fraction of the magnetic nanoparticles in 
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the ferrofluid. SAR in units of W/g is obtained using Eq. (4) as
43
/)( OFemTP , where, 43OFem is the 
mass of Fe3O4nanoparticles in ferrofluids. The results of magnetic hyperthermia measurements 
of CP and HT ferrofluid samples are shown in Fig. 4.4 with the inset showing the heating curves.  
 
Figure 4.4: Temperature dependent specific absorption rates (SAR) estimated for CP and 
HT ferrofluid samples of 12mg/ml concentration at 375 kHz ac field of amplitude 235 
Oe). The fitted data are represented by the black line. Inset shows the obtained heating 
curves for two samples. 
Clearly, the SAR data of the two samples are strikingly different although they both have 
similar average particle size. The solid lines in Fig. 4 are the best fits to the experimental SAR 
data using Eq. (4), the particle size distribution parameters and T
* 
values given in Table 4.1,  and 
treating the anisotropy constant, K, as a fitting parameter. The SAR fitting yields similar 
anisotropy constants for HT (~ 26 kJ/m
3
) and CP (~ 22 kJ/m
3
) ferrofluid samples. Clearly, the 
dipolar interactions play an important role in magnetic hyperthermia and reduce the value of 
SAR. 
We have generated SAR (room temperature) curves with and without the dipolar 
interactions. Figures 4.5 and 4.6 show the simulated SAR as a function of particle size (Do) using 
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Eq. (4.3), and obtained from the M (H) fitting (Table 4.1), and the K obtained from the fitting 
the experimental SAR data (Fig. 4.4).  
 
Figure 4.5: Theoretically generated SAR as function of particle size (Keff  = 22 kJ/m
3
 and 
 = 0.19) using Eq. (4) for the CP ferrofluid with and without the dipolar interaction. The 
symbol represents the experimental value for the CP ferrofluid, showing SAR would be 
higher in the absence of dipolar interactions for the same particle size distribution.  
 
 
Figure 4.6: Theoretically generated SAR as function of particle size (Keff  = 26 kJ/m
3
 and 
 = 0.35) using Eq. (4) for the HT ferrofluid with and without the dipolar interaction. 
The symbol represents the experimental value for the HT ferrofluid, showing SAR would 
be much higher in the absence of dipolar interactions for the same particle size 
distribution. 
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The calculations show that SAR increases with increasing particle size showing a peak at a 
critical size, beyond which SAR decreases with increasing particle size. Further, the peak in SAR 
shifts to higher particle size when the dipolar interactions are included in the simulation, and the 
curve becomes positively skewed as the value of increases (Fig. 4.6).   For our CP sample, the 
particle size is below the critical size and the dipolar interactions reduce SAR value by a small 
amount (Fig. 4.5). 
On the other hand, although the HT sample has a somewhat larger value of K, the peak 
SAR value is smaller (Fig. 4.6) than that of the CP sample (Fig. 4.5).  This is attributed to much 
larger size distribution (of MNPs in HT sample. When the dipolar interactions are introduced 
for this sample, the SAR value decreases further making it even smaller compared to that of the 
CP sample. We also note that the HT prepared particles have their size very close to the critical 
size needed to produce the maximum SAR, but the dipolar interactions reduce their magneto-
thermal heating efficiency.  
To understand the dynamic relaxation of the CP and HT prepared nanoparticles and to 
independently determine their effective magnetocrystalline anisotropy, we have measured the ac 
susceptibility of the powder samples as a function of temperature at different frequencies ranging 
from 350 Hz to 2 kHz. Figure 4.7 shows the imaginary part, ′′, of the ac susceptibility vs. 
temperature data for the samples. The ac magnetization curves of HT sample are broader 
compared to those of the CP samples, indicating a wider size distribution in the former sample. 
This is also in agreement with the magnetization data as discussed earlier. Further, the data 
clearly shows that the blocking temperature, TB, is frequency dependent and shifts towards 
higher temperatures with increase in frequency in both CP and HT samples implying thermally 
activated blocking process. The frequency dependence of TB for a collection of non-interacting  
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Figure 4.7: Temperature dependent out-of-phase susceptibility of powder samples at 
different frequencies (closed circles represent the data for CP sample and the open circles 
represent HT sample data). HT data has also been measured at 2 kHz in addition to the 
frequencies mentioned and the data is shown. 
particles is given by the Néel-Brown model given by equation 2.7, 






BB
m
Tk
KV
exp0  described in 
Section 2.2.1.  In the absence of an external field, KVm is the energy barrier for the reversal of the 
magnetic moment.  For a system of particles with dipolar interactions the energy barrier can be 
replaced by an effective anisotropy energy barrier, Eeff  = Keff <Vm>. Figure 4.8 shows the plots of 
ln () versus 1/TB for the two samples exhibiting the linear behavior. The results of the analyses 
are given in Table 4.2. The observed linear relationship with o ~ 10
-9
 s imply that Néel model 
correctly describes the superparamagnetic behavior of these MNPs.  We note that the anisotropy 
energy barrier is somewhat larger in HT prepared sample compared to that of the CP sample due 
to the presence of strong dipolar interactions. It is gratifying to note that the anisotropy constant 
determined from the ac susceptibility measurements are in close agreement with those 
determined from the hyperthermia measurements.  
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Figure 4.5: The plot of ln () vs. 1/TB for the CP and HT Fe3O4 powder samples. 
 
Table 4.2: Estimated values of magnetic anisotropy constant from the plot of ln () versus 1/TB 
Sample o (s) Keff <Vm> (J) Keff  (kJ/m
3
) 
CP-Powder 4.5 ×10
-9
 2.410-20 25.2± 4.3 
HT-Powder 1.4 ×10
-9
 2.910-20 24.9± 4.2 
    
4.4: Conclusions  
 In summary, we have prepared Fe3O4 nanoparticles by two different methods, co-
precipitation (CP) and the hydrothermal (HT) synthesis and measured their magnetic and 
magnetothermal properties.  Although both the samples have similar particle size (~ 12 nm) and 
saturation magnetization (~ 70 emu/g), yet they show drastically different heating rates (SAR) at 
room temperature ~ 110 W/g (CP sample) and ~ 40 W/g (HT sample). We have explained this 
observed reduction in SAR by taking into account the dipolar interactions and the distribution of 
magnetic core size of MNPs in ferrofluids. The HT ferrofluid shows nearly an order of 
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magnitude higher effective dipolar interaction and a wider distribution of magnetic core size of 
MNPs compared to that of CP ferrofluid. We have fitted the temperature dependent SAR data 
using linear response theory, incorporating an effective dipolar interaction, to determine the 
magnetic anisotropy constant of  the magnetic nanoparticles prepared by CP (22 ± 2 kJ/m
3
)  and 
HT (26 ± 2  kJ/m
3
) synthesis methods. These values are in good agreement with the magnetic 
anisotropy constant determined using frequency and temperature dependent ac magnetic 
susceptibility data obtained on the powder samples. Based on the analyses of the experimental 
data, we conclude that the HT method of synthesis leads to clustering of nanoparticles with 
strong dipolar interaction. The observed decrease in SAR of the HT sample, despite its somewhat 
larger anisotropy constant, is explained by taking into account the effects of magnetic dipolar 
interactions using the so called T* model.  
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CHAPTER 5 GADOLINIUM DOPED Fe3O4 NANOPARTICLES 
FOR MAGNETIC HYPERTHERMIA 
5.1: Introduction 
Integration of diagnostic imaging and therapeutic function into a single platform, so-
called “Theranostics”, is of great research interest as a new direction in nanomedicine research 
[1]. Theranostics refer to agents that allow the combined diagnosis, treatment and follow up of a 
disease, and are expected to contribute to personalized medicine. Superparamagnetic Fe3O4 is 
considered as an ideal vehicle in the development of theranostic nanomedicines as they can be 
multi-purposely used for magnetic resonance imaging (MRI) and targeted delivery of therapeutic 
agents such as anticancer drugs, siRNA and magnetic hyperthermia (MHT). Several different 
approaches of developing Fe3O4-based theranostic agent for multimodal and multifunctional 
applications are shown in the figure 5.1.  
 
 
 
Figure 5.1: Different approaches adopted in developing a SPION-based theranostic agent [141]. 
The application of superparamagnetic Fe3O4 in magnetic hyperthermia is well described 
in the earlier chapters. Another attractive application of superparamagnetic nanoparticles is to be 
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used as next generation of imaging probes in Magnetic resonance imaging (MRI). MRI is one of 
the most powerful and noninvasive medical diagnostic tools by monitoring the change in 
magnetization of hydrogen-protons in water molecules contained in a tissue, when placed in a 
magnetic field and exposed to a pulse of radio frequencies. This mapping provides a picture of 
anatomical structure due to the fact that protons in different tissues with varying water 
concentration and magnetic resonance properties react differently.  
Contrast agents are used to enhance the images as they affect the behavior of the protons 
in their vicinity sharpening the contrast. Contrast agents used in MRI are divided into two 
categories; T1 and T2 contrast agents based on their effect on the magnetic relaxation processes of 
the protons [142]. The reduction in the T1relaxation time (higher rate 1/T1), enhances the signal 
resulting a brighter image whereas the reduction in T2 relaxation time (higher relaxation rate, 
1/T2) decreases the signal, darkening the image. Most commonly used T1 contrast agents are 
paramagnetic compounds that are composed of metal ion with permanent magnetic moment due 
to unpaired electrons [gadolinium (Gd
3+
) or manganese (Mn
2+
)] and a chelating ligand, such as 
diethylene triamine pentaacetic acid, DTPA [142,143]. The chelate prevents the lanthanide from 
binding to chelates in the body making the paramagnetic lanthanide ion less toxic. T1 contrast 
agents mainly reduce the longitudinal (T1) relaxation which is due to energy exchange between 
the spins and surrounding lattice (spin-lattice relaxation) and result in a brighter signal. The 
second class, T2contract agents, consists of superparamagnetic nanoparticles, such as Fe3O4, 
have a strong effect on the transversal (T2) relaxation properties. In an external magnetic field, 
nanoparticles are magnetized and generate induced magnetic fields locally. These induced fields 
perturb the magnetic relaxation processes of the protons in the water molecules, especially the 
spin-spin relaxation (transverse relaxation). The transversal (T2) relaxation time decreases which 
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results in darkening of MR images. The role of superparamagnetic nanoparticles as T2 contrast 
agent explained above is depicted in figure 5.2. 
 
 
Figure 5.2: Magnetic nanoparticles as T2contrast agent for MRI. [144] 
 
When using nanoparticles as contrast agents for MRI, it is crucial that they are captured 
into the cells efficiently upon the exposure.  There are various research studies done on 
enhancing the MRI signal for cancer detection using superparamagnetic Fe3O4nanoparticles as 
T2 contrast agents [145-147]. For example, Jun et al. [148] have successfully synthesized 
superparamagnetic iron oxide nanoparticles of 9 nm size as magnetic probes for the in-vivo 
detection of cancer cells implanted in a mouse. In their research work, 2, 3-dimercaptosuccinic 
acid (DMSA) ligand is attached to the nanoparticles surface to obtain hydrophilic nanoparticles 
and the nanoparticles are further conjugated with the cancer-targeting antibody, Herceptin. The 
specific binding properties of Herceptin against a HER2/neu receptor over-expressed from breast 
cancer cells lead to the successfully detection of breast cancer cells (SK-BR-3) hence gives a 
dark MR image. 
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Even though both T1 and T2 mapping are powerful techniques, single mode contrast 
agents are not always sufficient in modern diagnosis as they have certain drawbacks and 
limitations [149]. For example, the dark contrast produced by T2 agents can also be generated 
from adjacent bones or vasculatures or there can be susceptibility artifacts due to the sharp 
change in magnetic field surrounding the contrast agent. Also, Gd-chelates (T1 agent) have high 
mobility which shorten their presence in the vascular system and raise possible toxicity issues. 
Thus, there is a growing interest in developing complementary T1–T2 dual-modal contrast agents, 
combining the advantages of positive and negative contrasts to obtain high sensitivity and 
biocompatibility for improved diagnosis [150]. Two different approaches of integrating T1 and 
T2species have been reported recently [149]. One is constructed by labeling T1 signaling 
elements (Gd species) on magnetic nanoparticles. In the study done by Bae  et al [151],Gd-
DTPA,a representative Gd chelate-based T1 MRI contrast agent, is covalently attached to 
dopamine-coated iron oxide nanoparticles. Their results demonstrated that the composite not 
only had the ability to improve surrounding water proton signals on the T1-weighted image, but 
also could induce significant signal reduction on the T2-weighted image. In another study 
reported by Santra et al. [152], Gd-DTPA is encapsulated within the poly (acrylic acid) (PAA) 
polymer coated superparamagnetic iron oxide nanoparticle (IO-PAA) conjugated to folic acid 
which act as the targeting ligand for breast cancer cells (HeLa cells). When nanoparobes 
internalized within the cells, which is acidic, composite magnetic nanoprobe degraded resulting 
in an intracellular release of Gd-DTPA complex with subsequent T1 activation which can be seen 
by MRI. Authors claim that thisT1 nano-agent could be used for the detection of acidic tumors. 
The other type of conjugated system consists of T1 paramagnetic elements embedded into T2 
magnetic nanoparticles. For example, Zhou et al [153] have synthesized Gd2O3-embedded iron 
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oxide nanoparticles with an overall size of 14 nm which can act as a T1 –T2 mutually enhanced 
dual-modal contrast agent for MR imaging of liver and hepatic tumor detection with great 
accuracy in mice. Xiao et al [154], have prepared PEGylated, Gd-doped iron oxide nanoparticles 
which is applicable as a T1–T2 dual-modal MRI contrast agent. Their in-vivo MRI results 
demonstrated the simultaneous contrast enhancements in T1- and T2-weighted MR images 
towards the glioma bearing mice. 
Even though the multi-functionality of superparamagnetic Fe3O4 nanoparticles based 
nano systems for drug delivery and imaging modalities [141] has been investigated widely, the 
possibility of incorporating magnetic hyperthermia and MRI is not explored much. In addition to 
be used as a T1 –T2 dual-modal contrast agent for MR imaging, Gd doped Fe3O4nanoparticles 
has the potential to act as an effective MHT agent [155]. Gd (III) is known to oppose net 
magnetic moment of Fe (III)/Fe (II) in oxides, reducing magnetizations [156-158]. Therefore Gd 
doping may reduce the hyperthermia efficiency but by using the correct amount of doping we 
can always explore the possibility of using them as both MRI contrast agents and hyperthermia 
mediators.  To the best of our knowledge, there are very few studies done on the magnetic 
hyperthermia efficiency of Gd doped Fe3O4nanoparticles [159,160]. Both the studies report 
higher SAR values for Gd doped (< 1%) Fe3O4nanoparticles compared to the reported values for 
undoped samples.  
 In this study, we synthesized Gd–Fe3O4 (2.5 at %) using co-precipitation technique, 
followed by the structural and magnetic characterizations. We found that the doping of Gd
3+
 ions 
into Fe3O4 spinel has significantly influenced the average crystallite size and the saturation   
magnetization. We conducted the magnetic hyperthermia experiments on the Gd doped Fe3O4and 
our detailed analysis demonstrate that the SAR value of the doped samples is similar to the 
59 
 
 
undoped Fe3O4despite the reduction of the magnetization upon doping. This study raises the 
possibility of using Gd–Fe3O4nanoparticles for multimodal contrast imaging and cancer 
treatment by hyperthermia. 
5.2: Synthesis and Structural Characterization 
Gd doped Fe3O4 nanoparticles were synthesized by a co-precipitation method, and coated 
with dextran according to the details explained in chapter 3. For a typical synthesis of 2.5 at% 
Gd–Fe3O4, aqueous solution of FeCl2.4H2O, FeCl3.6H2O and Gd(NO3)3were  prepared in a molar 
ratio of 1.00 : 1.925 : 0.075 in 25 ml volume followed by the addition of 250 ml of 1M NH4OH. 
The concentration of the produced ferrofluid was adjusted to 12 mg/ml for further measurements. 
Figure 5.3 shows the XRD pattern of both the Gd doped and undoped Fe3O4 nanoparticles.  
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Figure 5.3: XRD spectra for (a) Fe3O4 nanoparticles (b) Gd-doped Fe3O4 nanoparticles 
All the observed peaks in the XRD patterns can be indexed to the Fe3O4 crystal structure 
with no evidences for the presence of other crystalline impurity phases in significant amounts. 
According to the earlier studies Gd
3+
 ions tends to replace the Fe
3+
 ions of the octahedral sites in 
inverse spinel crystal structure [161]. From the XRD spectra, it is observed that Gd doping does 
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not disturb the Fe3O4crystal structure significantly. Using several intense XRD peak and the 
Debye-Scherer equation the crystallite sizes of the Fe3O4and Gd doped Fe3O4nanoparticles 
samples were determined to be 11.7±0.6 nm and 14.9±0.5 nm respectively. This increase in the 
crystalline size is consistent with the previous studies done on Gd doping on spinel structures 
[162]. TEM images of the two samples are shown in the Fig. 5.4. The undoped sample consists 
of roughly spherical nanoparticles with smaller polydispersitywhereas the Gd doped sample 
exhibits nanoparticles with rough edges with wider size distribution.  
 
 
Figure 5.4: TEM images of (a) Fe3O4 and (b) Gd doped Fe3O4 nanoparticles 
5.3: Magnetic Characterization 
The M-H data for undoped and Gd-doped Fe3O4 ferrofluid samples, recorded at room 
temperature, are shown in Fig. 5.5. The sigmoidal shape of the M (H) curves with nearly zero 
hysteresis confirms the superparamagnetic nature of these nanoparticles at room temperature. 
The saturation magnetization of Fe3O4 nanoparticles is measured to be ~ 72 emu/g whereas that 
of Gd-doped Fe3O4 nanoparticles is reduced ~ 52emu/g. This reduction in saturation 
magnetization at room temperature agrees with the observations in other reported studies 
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[154,162] and can be attributed to the fact that magnetic Fe
3+
 ions are supposedly getting 
replaced by the Gd
3+
 ions in the octahedral sites of the inverse spinel structure.  
 
Figure 5.5: M vs H curves for two ferrofluid samples fitted with the particle size distribution 
incorporated langevin function. The inset shows the resulting particle size distribution of the two 
samples. 
The black lines show the theoretical fit using a Langevin function for the magnetization as a 
function of H incorporating the particle size distribution and dipolar interactions using Eq. 2.11. The 
inset shows the magnetic core size distributions for two ferrofluid samples. The fitting 
parameters for the two samples are shown in Table 5.1.  
Table 5.1: Fitting parameters obtained from the M (H) fitting with modified Langevin 
function 
 
Ferrofluid Sample Ms(emu/g) D0 (nm) λ T
* 
(K) Davg (nm) 
Fe3O4 72 11.6 0.15 80 11.7±1.9 
Gd -Fe3O4 52 14.2 0.23 100 14.6±3.7 
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According to the fitting parameters, Gd-doped Fe3O4 nanoparticles have a higher average 
magnetic core size with a larger size distribution (14.6±3.7 nm) compared to the undoped Fe3O4 
nanoparticles (11.7±1.9 nm). Both the ferrofluid samples exhibit similar strength of magnetic 
dipolar interaction (T
*
 ~ 80-100 K).  
5.4: Magnetic hyperthermia characterization 
MHT measurements were carried out on the dextran coated Gd-doped and undoped 
Fe3O4ferrofluid samples at a field of 235 Oe and at a frequency of 375 kHz. The heating curves 
for two samples are shown in Fig. 5.6 (a) and from the plot it can be observed that the initial 
rates of heating for the two samples are roughly the same. From these heating curves the SAR 
values were obtained as a function of temperature taking into account of heat loss as described in 
the previous chapter. 
 
Figure 5.6: (a) Heating curves (Temperature vs time) for Fe3O4 and Gd-doped Fe3O4 ferrofluid 
samples under an ac magnetic field amplitude of 235 Oe and at a frequency 375 kHz.  (b) The 
temperature dependence of net SAR for two ferrofluid samples. The black line shows the 
theoretical fitting of the experimental data with the linear response theory. 
Figure 5.6 (b) presents the corrected experimental SAR data (symbols) as a function of 
temperature for both the undoped and Gd doped samples. Within the experimental error, the 
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room temperature SAR values for Gd-doped Fe3O4and undoped Fe3O4 ferrofluid are very similar. 
The temperature dependent SAR values were fitted to the linear response theory incorporated with 
the interactions and size distribution using the expression given in Chapter 2 (Eq. 2.23). The solid 
lines in Fig. 5(b) are the best fits to the experimental SAR data, using the particle size 
distribution parameters and T
* 
values given in Table 5.1and treating the anisotropy constant,  
K, as a fitting parameter. The SAR fitting yields a somewhat smaller anisotropy constant (~ 12 
kJ/m
3
) for Gd-doped ferrofluid compared to that of undoped ferrofluid (~ 21kJ/m
3
). 
Figure 5.7 shows SAR as a function of the magnetic core size (D0) in an AC magnetic 
field of 235 Oe and a frequency of 375 kHz at 298 K using the fitted values of Ms, D0, and λ 
obtained from our analysis of M-H (Table 5.1) and K values from MHT fitting of undoped 
Fe3O4and Gd-doped Fe3O4 ferrofluidsamples. 
 
Figure 5.7: Simulated SAR as a function of particle size. The symbols correspond to the 
experimental data. The parameters used are T = 298 K, H = 235 Oe, f = 375 kHz and 
values listed Table 5.1. 
For the simulation of SAR we used Eq. 4.3 that contains the dipolar interaction 
modification. The symbols correspond to the experimental SAR obtained for our two ferrofluid 
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samples. As explained in the previous chapter, SAR increases with D0 until it reaches a 
maximum value at a critical size and decreases with further increase in D0. The larger size 
distributions broaden the peak reducing the maximum SAR at the critical size. For both of our 
undoped and Gd-doped Fe3O4 samples, the particle size is below this critical size. It is seen here 
that, the critical sizes at which SAR is maximum shift to a lower value as K increases. Hence by 
reducing the amount of Gd doping amount it may be possible to obtain a Gd-doped Fe3O4 sample 
with a magnetic core size in between 12-14nm, magnetization and K higher than the values 
obtained for this Gd-doped Fe3O4 sample which will result in a higher SAR than the observed 
values. 
5.5: Conclusions 
Gd- doped iron oxide nanoparticles have been synthesized using the simple and widely 
used co-precipitation method and coated with dextran. The aim of the study was to understand 
the effect of the Gadolinium doping on the magnetic properties of nanoparticles and the 
associated magnetic hyperthermia response of the ferrofluids. Hence, the undoped iron oxide 
nanoparticles synthesized under the same experimental conditions were used as the control. The 
magnetization data reveals that the saturation magnetization decreases upon Gd doping. M vs H 
data were fitted with the langevin model incorporated with the log normal size distribution as 
well as dipolar interactions. Comparing the crystalline sizes (XRD) and magnetic core size 
distributions obtained from the langevin fitting of two samples, it is observed that Gd doping 
increases the magnetic core size and causes an increase in the polydispersity of the nanoparticles. 
Moreover, magnetic hyperthermia measurements were performed on dextran coated ferrofluids 
and the experimental SAR values (corrected for heat loss) were fitted using the linear response 
theory.   It is evident from the analysis that the magnetocrystalline anisotropy (K) is decreased by 
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several units upon Gd doping. The reduction in the saturation magnetization and K would 
generally result in a decrease in SAR but here the increased particle size distribution 
compensates the negative effect on SAR. Therefore, the obtained SAR value of the Gd doped 
Fe3O4 nanoparticles is similar to that of undoped Fe3O4 ferrofluid. Both the samples exhibits the 
same strength of interactions according to our analysis hence does not exhibit a significant 
impact on SAR. To conclude, the Gd doping on the Fe3O4 nanoparticles affect the morphology 
and the magnetic properties of Fe3O4 nanoparticles considerably but the magnetic hyperthermia 
efficiency of the samples were about the same within the error limits. By fine tuning the 
composition of Gd doped Fe3O4 nanoparticles, we may achieve a higher SAR value. The 
possibility of using Gd doped Fe3O4 nanoparticles as a dual modal T1-T2 contrast agent  is being 
currently explored by others and our magnetic hyperthermia results demonstrate that this 
material is a potential candidate for theronostics for multimodal contrast imaging and cancer 
treatment by hyperthermia.  
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CHAPTER 6 A COMPARATIVE STUDY OF MAGNETIC 
HYPERTHERMIA AND CYTOTOXITY OF DEXTRAN AND 
CITRIC ACID COATED Fe3O4 NANOPARTICLES  
6.1: Introduction 
In the design of magnetic nanoparticles for biomedical applications, surface coating plays 
an important role as it fulfills more than one function at a time. In general, the surface coating is 
important for three main reasons:  First, it provides the colloidal stability of ferrofluids 
preventing the particle clustering (reducing particle interactions). Second, the coating provides 
the biocompatibility which is a crucial factor in clinical applications. It ensures a double-sided 
isolation, preventing any toxic ion leakage from magnetic core into the biological environment as 
well as shielding the magnetic core from oxidization and corrosion. Third, it serves as a base for 
conjugating various functional groups such as targeting ligands, therapeutic drugs according to 
desired application. All these aspects were described in details in Chapter 2. In addition to that, 
surface coating can endow the nano system with long circulation properties making them 
“stealth” systems. When  nanoparticles are injected into the body during in vivo applications, 
they are often  recognized by reticuloendothelial system (RES) that eliminates any foreign 
substance from blood stream [163]. In this process, nanoparticles are rapidly attacked by the 
plasma proteins from RES and shuttled out of circulation to the liver, spleen or kidney which 
then cleared out from the body.  Also this RES accumulation often causes toxicity issues as well. 
The specific surface coatings can prevent the adsorption of these proteins, increasing the 
circulation time in blood hence maximize the possibility to reach target tissues [164]. For 
instance, it is well known that coating of hydrophilic polymers, mainly poly (ethylene glycol) 
(PEG), on the nanoparticles reduces nonspecific binding of the proteins resulting in stealth 
behavior. 
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The effect of the surface coating on magnetic properties and hence on the efficiency of 
the desired application is still not well understood. Therefore, fine tuning of surface coating 
materials is a major challenge in current research on the clinical applications of magnetic 
nanoparticles. During the surface coating on the nanoparticles, coatings molecules interact with 
the surface atoms of the magnetic core and may form a magnetically disordered layer. This can 
reduce the total amount of the magnetic phase. Different coatings exhibits different interactions 
with the magnetic core and therefore produce unique effective nonmagnetic layer thicknesses. 
However the discrimination between surface coating and finite size contribution is a difficult 
task especially in the smaller particles where the latter effect is dominant since the volume 
fraction of disordered surface spins are increased. There are many literature found on different 
surface coatings on different kind of magnetic cores and the surfactants effect on the magnetic 
properties [165-169]. In a study reported by Yuan et al. [168], effect of surfactant on magnetic 
properties was investigated using commercially available aqueous nanoparticle suspensions, 
FluidMAG-Amine, FluidMAG-UC/A, and FluidMAG-CMX, in parallel with oleic acid covered 
particles suspended in hexane and heptane. Their results reveal the reduction of magnetic phase 
in nanoparticles which varies with different coatings as well as with solvents. The magnetic 
reduction in different coatings was attributed to the different degree of surface spin disorder due 
to the absorbance of coatings and electric charge whereas the solvent dependent magnetic 
reduction was attributed to the difference in coating and the magnetic core interaction strengths 
in different solvents. 
The saturation magnetization is a main factor that determines the magnetic hyperthermia 
efficiency hence the change on the magnetic properties from the surfactant should influence SAR 
as well. Therefore a useful approach to improve the magnetic hyperthermia performance is to 
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optimize the surface coating to maximize the SAR. As for now there are conflicting SAR values 
obtained for a certain sized nanoparticle makes it difficult to evaluate the exact contributions of 
surface coating on the SAR. The study done by Liu et al [170], reports the possibility of 
increasing SAR by decreasing the surface coating thickness using highly monodispersed Fe3O4 
nanoparticles with different mPEG coating thickness. According to his explanation, a decrease in 
coating thickness lead to an increased Brownian loss, improved thermal conductivity as well as 
improved dispersibility resulting in increased in SAR. The optimized sample is further tested for 
magnetic hyperthermia in simulated physiological environments with protein (bovine serum 
albumin, BSA), blood sugar (dextrose), electrolytes (saline) and phosphate buffered saline 
(PBS). In another study reported by the same authors, superparamagnetic Fe3O4 nanoparticles 
after coating of Human-like collagen (HLC) show effective heat conduction under an AC 
magnetic field compared to uncoated sample despite of the slight reduction in saturation 
magnetization upon coating. According to Mohammad et al  it is also found that inorganic 
coatings improve the SAR value [171]. They found that gold coating retains the 
superparamagnetic fraction of the superparamagnetic Fe3O4 nanoparticles much better than 
uncoated nanoparticles alone and leads to higher magnetocrystalline anisotropy. In another study 
done by Filippousi et al. [165], authors use three diverse (different molecule length, polar head 
group and charge) and widely used surfactants, cationic cetyltrimethylammonium bromide 
(CTAB) surfactant, the nonionic polyvinylpyrrolidone, K30 (PVP) surfactant, and the anionic 
sodium cholate (S.C.) surfactant to investigate their possible influence on the magnetic properties 
and the heating response. Their results show that CTAB coated sample yields a lower 
magnetization (29.8 Am
2
 /kg) compared to the rest of the samples (~ 50 Am
2
 /kg) due to its more 
prominent oxidation and shows the lowest SAR among all samples.  
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 In our study presented in this chapter, we investigated the effect of surface coating on 
temperature dependent SAR using two biocompatible surfactants dextran and citric acid (CA). 
To compare the effect of coating, we used the same batch of Fe3O4nanoparticles for coating 
(post-synthesis coating) and studied the structural and magnetic properties as well as the 
colloidal stability of the dispersions. We also examined the influence of surface coating by 
systematically investigating the SAR of ferrofluids in slightly basic water solution as well as in 
simulated physiological environments with protein (bovine serum albumin, BSA).  
6.2: Characterization of dextran and citric acid coated Fe3O4 ferrofluids 
 The Fe3O4 magnetic nanoparticles were synthesized using the chemical co-precipitation 
route, as described in Section 3.1.1. The synthesized nanoparticles were then coated with dextran and 
CA based on the procedure outlined in Section 3.2.1 and Section 3.2.2.The concentrations of both the 
ferrofluids were adjusted to 12 mg/mL. The schematic diagram of the surface coated nanoparticles is 
shown in the figure 6.1. 
 
Figure 6.1: Schematic representation of dextran coated and citrate capped Fe3O4 
magnetic nanoparticle 
 The phase purity Fe3O4 crystalline structure of the as-synthesized nanoparticles was 
confirmed by the x-ray diffraction and the crystalline size was estimated to be 11.7±0.6 nm from 
Debye-Scherer analysis (XRD pattern not shown). The morphology of these nanoparticles was 
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investigated and the particle size distribution was also determined to be 13.2±2.3 nm using TEM 
as shown in figure 6.2. These obtained values are very similar to that of previous samples 
prepared for our earlier studies which confirm the reproducibility of the synthesis method. 
 
 
Figure 6.2: TEM images of as prepared Fe3O4and nanoparticles with the particle sizes fitted to 
log normal distribution. 
 The colloidal properties, zeta potential (ξ) and hydrodynamic size (DH), of the two 
ferrofluids were characterized using DLS measurements. The hydrodynamic size of dextran 
coated and CA coated Fe3O4 ferrofluids in aqueous media at pH of 7.4 were estimated to be 100 
±25 nm and 30 ± 5 nm respectively. The pH dependent ξ values were measured as shown in the 
figure 6.3. Both the ferrofluids show negative surface charges indicating their stability over a 
wide range of pH and the ξ values at pH 7.4 are estimated to be around -17 mV for dextran 
coated Fe3O4 and -27 Mv for CA coated Fe3O4.The large/small value of ξ indicates a more/less 
electrostatic repulsion between the nanoparticles which opposes the magnetic attraction acting 
between the nanoparticles. Therefore, our data indicates that, CA provides a higher stability 
compared to the dextran coating for the whole range of pH. 
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Figure 6.3.pH dependent zeta potentials of different surfactant coated Fe3O4 
nanoparticles 
6.3: Effect of surfactant coating on magnetic properties of Fe3O4 ferrofluids 
 The M (H) curves for both the dextran and CA coated Fe3O4 ferrofluids were obtained at 
300 K as shown in the figure 6.4. The saturation magnetization of both the ferrofluid samples 
was similar to the value obtained for uncoated Fe3O4 (~ 72 emu/g, reported in Chapter 5) 
indicating that the surface coating did not affect the magnetization of the sample. However, the 
magnetic core size of the CA coated ferrofluid obtained from the interaction incorporated 
Langevin function fitting analysis is slightly lower with a larger size distribution compared to the 
values obtained for the dextran coated ferrofluid as listed in Table 6.1. Even though we used the 
same nanoparticles for coating, due to the different reaction conditions and the different coating 
materials used, the surface of the nanoparticles are modified differently. The interactions 
parameter, T
*
, obtained for dextran and CA ferrofluids are in the range of 60-80K which 
indicates that both the coating provide excellent stabilityand reduce the inter-particle interactions 
producing a ferrofluid closer to ideal system.  
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Figure 6.4: M vs H curves for two ferrofluid samples fitted with the modified Langevin 
function. The inset shows the resulting particle size distribution of the two samples. (red line 
represents CA coated sample, blue line represents Dextran coated sample) 
 
Table 6.1: Fitting parameters for Dextran and CA coated Fe3O4 ferrofluid samples. 
 M-H curve fitting 
Ferrofluid Sample 
Ms 
(emu/g) 
D0 (nm)  T
* 
(K) Davg(nm) 
Dextran-Fe3O4 74 11.6 0.15 80 11.7±1.8 
CA _Fe3O4 72 11.2 0.21 60 11.5±2.4 
6.4: Magnetic hyperthermia of dextran and citric acid coated Fe3O4 ferrofluids 
 The magnetic hyperthermia measurements were made on ferrofluids samples, with 12 
mg/ml concentration, using an ac magnetic field of amplitude of 235 Oe and frequency of 375 
kHz in the temperature range of 25 - 50 
o
C, as described in earlier chapters.  The heating curves 
and the corresponding plots of SAR as a function of temperature shown in Fig. 6.5 for both 
dextan and CA coated samples. The initial SAR values of the samples are very similar (105-110 
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W/g) within the experimental error limits, and it decreases with the increase of temperature. 
Dextran coated ferrofluid shows a higher decrease in SAR with temperature whereas this 
decrease is smaller in CA coated ferrofluid. This difference may due to the different size 
distributions as well as the thermal properties of the two ferrofluids. Using the parameters listed 
in Table 6.1, we fitted the temperature dependent SAR curves using modified linear response 
theory to obtain the values of K as a fitting parameter. Interestingly, both the samples yield very 
similar values 21-22 KJ/m
3
. 
 
Figure 6.5: Left:Temperature vs time curves for dextran and CA coated Fe3O4 ferrofluid samples 
of 12mg/ml concentration at a frequency 375 kHz and under acmagnetic field amplitude of 235 
Oe.  Right: The temperature dependence of net SAR for two ferrofluid samples. The black line 
shows the theoretical fitting of the experimental data with the linear response theory. 
6.4.1: Effect of Concentration on the magnetic hyperthermia efficiency 
In order to understand the stability of the ferrofluids upon dilution and its effect on the 
magnetic hyperthermia efficiency, we conducted a series of experiments to measure the SAR at 
different concentrations. From the stock concentration of 25 mg/ml, we prepared dilute 
ferrofluids with concentration of 12mg/ml, 6 mg/ml and 3 mg/ml, using DI water as the solvent. 
The SAR values obtained for different concentrations of two ferrofluid samples at room 
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temperature are shown in the Fig. 6.6 (filled symbols). A decrease in SAR was observed upon 
dilution for both ferrofluids. In general, it has been observed that a decrease in concentration 
would result in an increase in the inter-particles distance, decreasing the dipolar interactions 
between particles which in turn results in an increase in SAR [172-174]. However the 
contradictory results obtained from our data may be due to the poor quality of the diluted 
samples containing clusters/aggregates formed upon dilution. Therefore, when diluting the 
samples, more precautions might be taken or we could try to dilute with a week base solution.  
 
Figure 6.6: SAR values of dextran and CA coated Fe3O4 samples at different 
concentrations at 25 °C. All the data was obtained at a frequency of 375 kHz and ac 
magnetic field amplitude of 235 Oe. 
6.4.2: Effect of the solvent media on the hyperthermia efficiency 
Whenever nanoparticles encounter biological systems, interactions take place between 
their surfaces and biological components such proteins, membranes, phospholipids, DNA 
forming so called “protein corona” around the nanoparticles [175,176]. Upon the exposure, faster 
binder interacts with the nanoparticle surface forming the initial corona, however they eventually 
are replaced by proteins with the highest affinity to the surface (Vroman effect) [177]. The initial 
corona formed on short time scales (seconds to minutes) is called “soft” corona whereas the one 
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that forms in later times over period of hours is called “hard” corona. The adsorption of serum 
proteins on the nanoparticles surfaces in a biological system has been widely studied, often 
focusing on the effect on cell uptake and cytotoxicity of the particles [178-181]. The formation 
of corona depends on the surface properties of the particles [182,183] and can influence the 
aggregation behavior of nanoparticles in biological media, which in turn can affect their 
performance for desired applications. Therefore, apart from the optimization of the properties of 
the magnetic core and surface coating for high performance magnetic hyperthermia, it is 
necessary to ensure its performance in the physiological environments. In the work reported by 
Khandhar et al [184], authors use poly(maleic anhydride-alt-1-octadecene)-poly(ethylene glycol) 
(PMAO-PEG), an amphiphilic polymer coated Fe3O4nanoparticles of three different sizes, 13 
nm, 14nm and 16 nm, to study the magnetic hyperthermia efficiency in cell growth medium 
(CGM)  similar to biological environment. Their results show an increase in hydrodynamic sizes 
in all three samples upon exposure to CGM. SAR is reduced (30%) only in 16 nm size sample 
while other two samples did not exhibit any significant decrease in SAR. Authors suggest that 
the increase in hydrodynamic volume prolongs Brownian relaxation while Neel relaxation is 
unaffected. Hence in 13 and 14 nm samples where SAR is mainly due to Neel relaxation, SAR 
was not affected.  But in 16 nm samples, in which there is a contribution from Brownian 
relaxation to heat dissipation, the SAR dropped due to the increase in Brownian relaxation.  
We investigated the magnetic hyperthermia efficiency of dextran and CA coated Fe3O4i 
ferrofluids in cell growth medium which contains serum proteins similar to physiological 
environments. From the stock solutions (25 mg/ml), 3mg/ml concentration of dextran and CA 
coated ferrofluids samples were prepared using cell growth medium (CGM) and DI water. The 
ferrofluid samples were subjected to an alternating magnetic field of amplitude, 235 Oe and the 
76 
 
 
frequency of 375 kHz and the time dependent temperature was measured followed by the 
analysis described in the earlier chapter. The SAR of dextran coated samples in DI and CGM 
were estimated to be 63 W/g and 72 W/g respectively which indicate that their performance is 
not much affected by the medium if not enhanced. However, SAR values obtained for CA coated 
samples in DI and CGM, 78 W/g and 38 W/g, implies that their efficiency is heavily reduced 
when exposed to physiological environments. The summary of the results of solvent dependent 
SAR is shown in figure 6.6. 
In order to explore the reason for this reduction of hyperthermia efficiency in CGM, we 
measured the hydrodynamic sizes of dextran and CA coated ferrofluids samples at different 
incubation times from few minutes to 24 hours upon exposure to CGM. As seen from the 
measured values, the hydrodynamic sizes of both the ferrofluids are increased, each at different 
rates (see Fig 6.7). The increase in the sizes can be attributed to the formation of protein corona 
upon the nanoparticle exposure to the serum proteins in CGM.  Dextran and CA coating endow 
the nanoparticles surface with different surface chemistries. For example CA coating provides 
the more active carboxyl functional groups making the surface hydrophilic andincreasing the 
electrostatic repulsion between the particles. On the other hand, dextran coating has hydroxyl 
groups, and interactions between the particles are reduced mainly due to steric repulsion than 
electrostatic repulsion. When CA coated Fe3O4 is exposed to serum proteins, the proteins rapidly 
bind to their surface forming a protein corona. As a result its hydrodynamic size increases 
quickly and reaches to the maximum value within 5 hours. This in turn reduces the stability of 
the ferrofluid, leading the particles to form aggregates reducing the SAR value. 
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Figure 6.7: Hydrodynamic sizes of dextran and CA coated Fe3O4 samples at different 
times at 25 °C. Red symbols represent CA coated sample, blue symbols represent 
Dextran coated sample. Closed symbols are for ferrofluids diluted using CGM and open 
symbols are for ferrofluids diluted with DI. 
Compared to CA coated particles, dextran coated nanoparticles show much stability at 
least during first 3 hours upon exposure to the serum proteins. The formation of the corona takes 
place at a slower rate which may due to the steric hindrance and the low activity of hydroxyl 
groups. Therefore its hyperthermia efficiency is not reduced as in CA coated Fe3O4 sample. A 
schematic representation of the protein corona formation is shown in Fig. 6.8. However, when 
analyzing the data obtained from hydrodynamic size measurements, it should also be noted that 
not only the protein corona but also free-protein clusters are likely to influence the results. 
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Figure 6.8: Sketched evolution of the nanoparticle agglomeration process when in 
contact with protein-rich medium such as DMEM + FBS  
6.5: Cytotoxicity studies on human pancreatic cancer cells 
As mentioned earlier, one of the basic and an important requirement that should be 
fulfilled by nanoparticles for them to be used for biomedical applications is the non-toxicity. We 
tested the cytotoxicity of dextran and CA coated Fe3O4 ferrofluids by performing trypan blue 
exclusion technique [185], an established cytotoxicity protocol, followed by cell counting using 
hemocytometer [186] on human pancreatic cancer cells, Mia PaCa 2. Same amount of MIA 
PaCa-2 cells were seeded in 100 mm dishes containing 10 ml of cell growth medium (10% fetal 
bovine serum,5% penicillin in Dulbecco’s modified essential medium),and were incubated for 24 
hours at 37 °C in a humidified 5% CO2 atmosphere in order to make cells attached to the bottom 
of the culture plate. Then half of the medium was replaced with the fresh medium containing 
dextran and CA coated Fe3O4 ferrofluids of 200 µg/mL concertation which makes the final 
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concentration 100µg/mL in each dish. Fresh cell growth medium without nanoparticles were 
used for the control experiments. After incubating the cells with the nanoparticles coated with 
dextran and CA for 24 and 48 hours, the supernatant was taken out and stored in a corning flask. 
This supernatant contains any dead cells that are detached from the cell bottom. Then 2 ml 
trypsin was added, incubated for 3 minutes in the incubator followed by the addition of the cell 
growth medium. This cell solution was mixed with the corresponding supernatant that was stored 
previously. Now the cells were centrifuged at 1500 rpm for 3 minutes, supernatant was removed 
and the cell pellet was dissolved in 2ml of cell growth medium. Out of the concentrated cell 
suspension, 100 µL was taken and mixed with 100 µL of 0.4% trypan blue solution. Then 10 µL 
of the resultant solution was loaded on a hemacytometer and examined immediately under a 
microscope at low magnification. The cells that are dead or non-viable will take up trypan blue, 
result in blue color. The number of blue staining cells and the number of total cells were counted 
to estimate the cell viability using the Eq. 6.1. The experiments were done in triplicates. 
 
% viable cells = [1 −
Number of blue cells
Number of total cells
] × 100%     (6.1) 
 
According to the results, both the cells that are exposed to dextran and CA coated Fe3O4 
nanoparticles show the same viability as the normal cells that are not exposed to the 
nanoparticles. This indicates that at the concentrations of 100 µg/mL or lower, nanoparticles 
coated with dextran and CA do not show any toxic effect on the cells. The cytotoxicity results 
are shown in the Figure 6.9. 
80 
 
 
 
 
Figure 6.9: Cytotoxicity for dextran and CA coated Fe3O4 nanoparticles on Mia PaCa 2 
cells as determined by counting live cells using Trypan Blue assay. Experiments were 
conducted in triplicate with n = 3. Error bars represent the standard deviation.  
6.6: Conclusions 
In this study we investigated the effect of two coatings, dextran and CA, on the colloidal 
and magnetic properties of Fe3O4nanoparticles as well as their impact on magnetic hyperthermia 
efficiency. Both the ferrofluids (dextran and CA coated) show similar magnetic properties, with 
same value of SAR in DI water. Our concentration dependent magnetic hyperthermia results 
indicate that the dilution of the sample should be done with extensive care as it may promotes 
cluster formation which in turn reduces the SAR value. Moreover, upon exposure to cell growth 
medium that mimics the physiological environment, formation of corona was observed for both 
dextran and CA coated nanoparticles as seen from the hydrodynamic size measurements. It was 
observed that in CA coated particles where, this protein corona forms faster, in several minutes 
to hours, that causes aggregations in solution which in turn reduce SAR by ~ 45%. But dextran 
coated nanoparticles show a better stability at least within first 3-6 hours upon exposure to the 
proteins in the cell growth medium exhibiting excellent performance in both water and simulated 
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physiological conditions. The cytotoxicity studies done on human pancreatic cancer cells 
indicate that both dextran and CA coated Fe3O4 ferrofluids are nontoxic to the cells at or below 
100 µg/mL concentration. Though further in vivo study is necessary in the future, these results 
imply that the dextran coated Fe3O4 dispersion could maintain their high heating capacity in 
physiological environments while CA coating require further surface modification to reduce the 
non-specific protein adsorption. 
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CHAPTER 7 TIME-DEPENDENT CELLULAR UPTAKE AND 
DISTRIBUTION OF DEXTRAN-COATED IRON OXIDE 
NANOPARTICLES 
7.1: Introduction 
Aa mentioned in the earlier chapters, superparamagnetic Fe3O4nanoparticles (SPIO) are 
currently one of the most important and acceptable nanoparticles since they can be multi 
purposely used such as for imaging, targeted drug delivery, magnetic hyperthermia, and cell 
separation with external magnetic manipulation [49,187-189]. Fabricating a biocompatible, well 
dispersed, stable colloidal dispersion of the nanoparticles with good magnetic properties is 
crucial for clinical applications and intensive research continue to be carried out to further 
improve the biocompatibility and dispersibility. Nanoparticles in the range of 10-200nm are 
generally considered to be ideal for the biomedical applications since they are taken up by the 
liver and spleen for clearance from the body. The cellular uptake, bio distribution, molecular 
response and the potential toxicity of the SPIO nanoparticles are mostly based on the particles 
size, physical shape, and surface chemistry [190]. Importantly, these cellular responses also 
depend on the cell type [191]. 
Although, extensive studies have been carried out on the synthesis, biocompatibility, 
surface modifications [190,192-195], cytotoxicity [196-198], and the in vivo targeting of 
Fe3O4nanoparticles, a complete understanding of their interaction and subcellular distribution in 
cells is yet to be fully realized. In present study, we have determined the traffic, distribution, and 
the cytotoxic effects of the dextran coated Fe3O4 nanoparticles on Mia PaCa 2, human pancreatic 
cancer cells. The mass spectroscopy was used as the tool to investigate the time dependent 
distribution of the nanoparticles. 
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7.2: Synthesis and characterization of Fe3O4 nanoparticles 
Fe3O4 nanoparticles were synthesized by the co-precipitation technique as described in 
section 3.1.1 with slight modifications. Here, the aqueous solution of Fe
2+
 / Fe
3+
 was kept under 
constant magnetic stirring at 800rpm and 125 ml of 2M NH4OH solution was added drop wise 
into the mixture. The nanoparticles were isolated with a magnet and washed several times with 
deionized water until a neutral pH was reached. The portion of synthesized nanoparticles was air 
dried and the resulting powder was used for the structural and magnetic characterization. The 
XRD pattern for the bare Fe3O4 nanoparticles is shown in Fig 7.1.  
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Figure 7.1: XRD pattern of synthesized 8 nm size Fe3O4 nanoparticles. Sample was 
deposited on a glass substrate from acetone dispersion. Diffraction pattern was collected 
on a Rigaku MiniFlex 600 X-ray diffractometer under CuKα radiation (λ = 1.5418 Å). 
The peaks observed in this pattern were consistent with those of standard XRD pattern of 
Fe3O4 reported previously (reference JCPDS No. 82-1533) which confirms crystalline nature of 
the synthesized Fe3O4 nanoparticles with Face centered cubic structure. Also, the absence of any 
unknown peaks confirms that there are no secondary phases formed and there is no significant 
presence of crystalline impurities in the sample. The crystalline size of MNPs was estimated to 
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be 7.2±0.8 nm by the use of Debye-Scherer’s equation. TEM images of the IONPs (Fig. 7.2) 
reveal that the nanoparticles are spherical with a narrow particle size distribution. To determine 
the particle size distribution, the sizes of the particles from multiple images were measured, and 
the obtained sizes were sorted into a histogram, and the histogram data was fitted to a log-normal 
distribution function as described in the earlier chapters. The histogram and the lognormal fits 
are shown in the inset of Fig. 2.  The average particle size and the standard deviation of the 
distribution were estimated to be 7.7 nm and 1.7 nm respectively.  
  
 
 
 
 
   
 
 
 
Figure 7.2: TEM Image of bare Fe3O4 nanoparticles (A), size distribution plot with log normal 
fitting (B). 
M (H) curve shown in Fig. 7.3 demonstrate superparamagnetic behavior (no coercivity). 
M (H) curve shown in Fig. 7.3 demonstrate superparamagnetic behavior (no coercivity).The 
saturation magnetization of the Fe3O4 nanoparticles at 300 K was found to be 61 emu/g with a 
maximum applied field of 10 kOe, which is lower than the reported values of bulk Fe3O4 (92 
emu/g)[199]. The reduction in saturation magnetization may be attributed to the surface disorder 
or spin canting at the particles surface [139]. 
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Figure 7.3: M (H) curve for 8 nm Fe3O4 nanoparticles at 300 K demonstrating the 
superparamagnetic behavior with saturation magnetization of 61emu/g. 
7.3: Conjugation of FITC to dextran-functionalized Fe3O4 nanoparticles  
The synthesized nanoparticles were then coated with dextran to obtain the well suspended 
ferrofluid and cross linked using epichhlrohydrin according to the detailed description presented 
in Section 3.2.1 and 3.2.3 respectively. Conjugation of FITC to dextran-functionalized 
nanoparticles was carried out using an established published procedure[200] , details of which is 
presented in Section 3.2.4. 
7.4: MIA PaCa-2 cellular studies 
To investigate the interaction between cells and the synthesized Dex-Fe3O4-FITC 
nanoparticles, MIA PaCa-2 cells were exposed to them and the cellular uptake, distribution, and 
cytotoxicity were evaluated as described here. MIA PaCa-2 human pancreatic cancer cells were 
grown on poly L-lysine-coated petri dishes in Dulbecco’s modified essential medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 5% Penicillin-Streptomycin. Approximately, 5 × 
10
4
 MIA PaCa-2 cells were seeded in 35 mm dishes containing 2 ml of DMEM-10% FBS-5% 
Penicillin-Streptomycin, were incubated for 24 hours at 37°C in a humidified 5% CO2 
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atmosphere. After 24 hours, half the medium was removed, and replaced with fresh medium 
containing FITC labeled Dextran coated SPIO nanoparticles so that the final concentrations are 
0, 5 µg/ml, 50 µg/ml, 125 µg/ml. Cells were imaged using an Olympus FSx100 fluorescence 
microscope in the green channel (excitation at 485 nm, emission at 530 nm). Fluorescence 
images of the cells were taken at different time intervals: 0 hour, 6 hours, 24 hours and 48 hours. 
After 48 hours, cells were washed three times with PBS solution to get rid of unbound 
nanoparticles, trypsinized, centrifuged, and 5 × 10
4
 of cells were cultured in new 35 mm dishes. 
These cells, in which nanoparticles are internalized, were incubated at 37 °C in a humidified 5% 
CO2 atmosphere for another 3 days. After 3 days, the old medium was replaced with fresh 
medium, followed by imaging. Experiments were performed in triplicates.  
The fluorescence images taken at different time intervals such as at 0h, 24hour, 48 hours 
are shown in Fig. 7.4, and the increase in the fluorescent signals over time demonstrates 
increased accumulation of the FITC functionalized SPIO in cells. According to the images, the 
SPIO nanoparticles were internalized within cells during 48 hours of incubation at 37°C. The 
SPIO nanoparticles were shown to exhibit dose dependent cytotoxicity and shown to be safe up 
to the concentration level of 100 µg/ml on human cells [201]. Interestingly, even after 3 days of 
incubation (Fig. 7.5), nanoparticles were still present in the cells. The presence of the 
nanoparticles within the cells clearly indicates the inheritance of the nanoparticles from the 
parent cells during cell division. Also at this time point, the cells incubated with 125 µg/ml of 
SPIO show a significant decrease of cell number, which may be due to the inhibition of cell 
division caused by the prolonged accumulation of nanoparticles. 
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Figure 7.4: Images demonstrating the time-dependent binding and accumulation of FITC 
functionalized dextran coated SPIO nanoparticles with cultured MIAPaCa2 cells. Top to Bottom: 
0h, 24h, and 48h. Phase images of cells (a), (c), (e), Left to right: corresponding fluorescent 
images. (b), (d), (f). 
 
 
Figure 7.5: Phase image (a), fluorescent image (b), of cells showing the presence of FITC 
conjugated dextran coated SPIO nanoparticles within the cells after 3 days of accumulation 
indicating the inheritance of nanoparticles from parent cells to daughter cells during cell division. 
Overlaid image of phase and fluorescent images (c) demonstrate that most of the nanoparticles 
are at the membrane (white arrow heads) while small amount can be seen in the nuclei (red 
arrow heads). 
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In agreement with the literature, there was no evidence of cytotoxicity observed in our 
data during the first 48 hours as shown in Fig.7.6. 
 
Figure 7.6: Cytoxicity results for dextran-FITC coated SPIO nanoparticles on MIA PaCa2 cells 
at three different concentrations. Note that cells were washed at 48 hours to remove unbound 
nanoparticles and were incubated for another 3 days.  
7.5: SDS-Page 
In order to study the time dependent binding of the specific proteins the experiments were 
carried out as following. Cells were lysed using 2% Triton, centrifuged for 1 minute at 1000rpm. 
The supernatant was removed and the pellet containing nanoparticles bound proteins was washed 
using PBS pH 7.4.  The nanoparticle-associated proteins were resuspended in Laemmli [15] 
reducing sample preparation buffer, boiled for 2 min, and used for SDS-PAGE. SDS 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) was run in order to separate nanoparticles 
bound proteins based upon their size. The gels were then stained using Coomassie Blue 
overnight, de-stained for 3-4 hours and imaged.  
Assessment of the protein profile associated with the nanoparticles from SDS-PAGE, at 
different times following incubation with cells, demonstrates a time-dependent distribution and 
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association of the nanoparticles with different cellular compartments as reflected from their 
different protein profiles (Fig. 7.7).  
 
Figure 7.7: Coomassie stained SDS page gel image of protein bands associated with 
Fe3O4 nanoparticles at different time points. 
The SDS-PAGE demonstrates differences in some of the protein bands which change 
with time, and are shown as A, B, C. The bands A and B are seen in 24 and 48 hours but not 
before or after thatwhereas the band C appears only at 48 hours, suggesting association of the 
nanoparticles with different subcellular compartments at different times following exposure to 
cells.  
7.6: Mass Spectroscopy data 
Mass spectrometry was performedto identify the proteins associated with thebands 
observed from SDS page gel. One of the gel bands (Band B in Figure 7.7) which showed 
different optical densities at different time points during 0-72 hour time interval was selected. 
The corresponding band of the control and the experimental samples at each time point was cut 
and prepared for mass spectroscopy measurements. The proteins associated with these gel bands 
were identified and the proteins present at different time points are listed in Table 1.  
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Table 7.1:  List of proteins that are bound to the nanoparticles at different time points as 
identified by mass spectrometry. The sub cellular organelles associated with each protein are 
listed in the right column revealing the possible location/distribution of the nanoparticles after 
been exposed into the cells. 
 
Protein Sub cellular organelle 
2
4
 h
o
u
rs
 
Flotillin-2 Cell membrane, Endosome 
Actin-like protein 6A Nucleus  
Septin-7 Cytoplasm 
DnaJ homolog subfamily A member 1 Membrane, Nucleus, Cytoplasm 
Nucleoporin Nup43 Nucleus, Chromosome 
4
8
 h
o
u
rs
 
Glutamate receptor ionotropic, delta-2 Cell membrane 
Heterogeneous nuclear 
ribonucleoprotein H 
Nucleus › nucleoplasm 
RuvB-like 2 Nucleus, cytoplasm, membrane 
Eukaryotic translation initiation factor 2 
subunit 3 
Cytoplasm 
Pigment epithelium-derived factor  Melanosome, Secreted  
Wnt inhibitory factor 1 Secreted  
 
7
2
 h
o
u
rs
 
Cytochrome b-c1 complex subunit 1, 
mitochondrial 
Mitochondrion inner membrane 
Ubiquitin-60S ribosomal protein L40 Cytoplasm, Nucleus 
Actin, aortic smooth muscle Cytoplasm › cytoskeleton 
Cathepsin D Lysosome 
2
4
 &
 4
8
 h
o
u
rs
 
Protein DEK Nucleus 
Polymerase delta-interacting protein 3 Nucleus. Nucleus speckle. Cytoplasm 
Cell growth-regulating nucleolar protein Nucleus 
Protein MAK16 homolog Nucleus › nucleolus 
Ribosome production factor 1 Nucleus › nucleolus 
DDB1- and CUL4-associated factor 13 Nucleus › nucleolus 
WD40 repeat-containing protein SMU1 Nucleus.  Cytoplasm 
Core histone macro-H2A.1 Nucleus. Chromosome 
26S protease regulatory subunit 7 cytoplasm, Nucleus 
 
91 
 
 
Data reveals the possible entrance of nanoparticles through endocytosis and targeted to 
the cell nuclei within 48 hours. At 72 hours Cathepsin D , which is present in the lysosome, was 
identified which suggests that the clearance of the nanoparticles through the lysosome does not 
occurs immediately after the entrance, instead  proves the prolong accumulation of the 
nanoparticles in the cells. 
Also we determined the distribution of nanoparticles within cells at different time points 
from the protein data and shown in Figure 7.8. From that also it can be observed that 
nanoparticles are present in the nucleus within 24 hours and the clearing occurs only after 48 
hours, since the relative percentage of proteins associated with nanoparticles has decreased at 72 
hours. 
 
Figure 7.8: Schematic representation of distribution of Fe3O4 nanoparticles within cells 
at different time points estimated from the mass spectroscopy data.  
7.7: Conclusions 
In summary, the current study we have successfully functionalized nanoparticles for use in 
investigating their binding and distribution in Mia PaCa-2 human pancreatic cancer cells. We 
have investigated the traffic, distribution, and cytotoxicity, associated with these Fe3O4 
nanoparticles, and demonstrated that there is a time-dependent distribution of these nanoparticles 
into different cellular compartments. Furthermore, immunocytochemistry using co-localization 
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of the nanoparticles with specific subcellular immune-markers is being carried out to further 
confirm results from mass spectrometry. Results from these studies promise optimized drug 
delivery and treatment of various diseases including cancers.  
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CHAPTER 8 SUPERPARAMAGNETIC IRON OXIDE 
NANOPARTICLES POTENTIATE CELLULAR ENTRY AND 
RELEASE OF CANCER DRUG 
8.1: Introduction 
The various properties of nanoparticles (NPs) have been extensively explored for they 
offer a broad spectrum of usage ranging from applications in electronic materials to medical 
therapy [202].  In the last decade, gold [203,204], silver [205,206] and magnetic nanoparticles 
[207] especially iron oxide emerged as potential candidates for the diagnosis and treatment of 
various forms of cancer. The interaction of these NPs with cancer cells is widely studied for 
careful understanding of several drug delivery and therapeutic approaches [208-210]. The Fe3O4 
NPs [211] with their very unique superparamagnetic behavior play a prominent role in 
modernizing the field of nanomedicine [190,212-214]. Several modifications including surface 
functionalization of these Fe3O4NPswith anti-cancer drugs especially doxorubicin (Dox) have 
been conducted over the last few years to investigate their efficacy when it comes to cancer 
eradication [215]. Previous studies have reported that PEG (Polyethylene Glycol) functionalized 
porous silica shell onto doxorubicin-conjugated Fe3O4 nanoparticle cores [216], PAMAM 
(Poly(amidoamine)) coated Fe3O4 nanoparticles-doxorubicin complex [217], doxorubicin loaded 
Fe3O4 nanoparticles modified with PLGA-PEG copolymers [218] could potentially be very 
promising in therapeutic cancer treatment. Pancreatic cancer, a very devastating form of cancer, 
is one of the major causes of death in the United States [219]. Dox conjugated NPs have been 
extensively used for efficient drug delivery especially in human breast cancer cells. The anti-
cancer drug Dox and the targeting ligand conjugated to the surface of a polymeric nanoparticle 
works effectively for drug delivery in the human breast cancer cells. However, interaction of 
nanoparticles with the human pancreatic cancer cell lines is not much explored. So a detailed 
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investigation to understand the interactions and the intracellular distribution of these 
nanoparticles into the human pancreatic cancer cells is very crucial.  
In this chapter, we primarily present our work on the novel conjugation of Dox with a 
labeling dye (FITC) onto dextran coated Fe3O4 nanoparticles using existing EDC/NHS technique 
and their incorporation into the human pancreatic cancer cell line (MIA PaCa-2) for specific drug 
targeting. This unique drug-dye dual conjugation of Fe3O4 NPs after penetration through the cell 
membrane following phagocytosis [220], show a steady release of Dox into the nucleus of the 
malignant cells. Our studies demonstrate that association of Dox onto the surface of 
nanoparticles enhances its penetration into the cancer cells as compared to the unconjugated 
drug. 
8.2: Experimental details 
8.2.1: Synthesis and characterization 
The superparamagnetic Fe3O4 nanoparticles were synthesized coated with dextran and 
cross linked following the exact procedure as described in Chapter 7.  
8.2.2: Double labeling of dextran coated Fe3O4 nanoparticles with doxorubicin and FITC    
(Dex- Fe3O4-DOX/FITC) 
The pH of the dispersion (10 ml) of crosslinked SPIO NPs having a concentration of 
4mg/ml was adjusted to 11 using the NaOH base (0.1 M) under continuous stirring for 1 h at 
room temperature while purging with N2 gas. 100mg of monochloroacetic acid (MCA) was then 
slowly added to the solution and the mixture was heated at 60˚C in a water bath and under N2 
atmosphere. The reaction mixture was then dialyzed against deionized water to obtain the CMD-
SPIO. The DOX and FITC were attached to the CMD-SPIO NPs through EDC/NHS chemistry. 
10 mg of EDC and 6 mg of NHS was added to 2.5 ml CMD-SPIO NPs suspension and stirred for 
15 minutes at room temperature to activate the carboxyl groups. 1µmol of DOX was added to 
95 
 
 
this mixture and subjected to stirring for 10 minutes, followed by the addition of 1 ml Ethylene 
diamine hydrochloride (EDA). The resulting mixture was then dialyzed for 24 h to get rid of 
unbound drug and EDA. 1µmol of FITC solution was added to this amino functionalized CMD-
SPIO NPs solution. After 2 h the mixture was subjected to short time interval frequent dialysis. 
The final concentration of the SPIO NPs in the resulting DOX/FITC conjugated CMD-SPIO NPs 
(Dex-SPIO-DOX/FITC) was estimated to be 2 mg/ml. All these experiments were carried out in 
the dark. 
8.2.3 Estimation of drug/dye encapsulation efficiencies 
The fluorescence (FL) intensity of the fluorescent dyes was estimated using a Hitachi F-
2000 Fluorescence spectrophotometer. The calibration plots of fluorescence intensity versus the 
concentration of the drug/dye were initially obtained as follows. The different concentrations (1, 
5, 10, 25, 50 µg/ml) of DOX and FITC solutions were prepared from a stock solution of 500 
µg/ml. A drop (equivalent to 10 µl) of DOX and FITC solutions was then added on a glass slide 
at a time and the fluorescence images were taken at an optimized exposure time with the red 
channel and the green channel respectively under the 40X oil immersed objective lenses (n=4).  
For each concentration, the intensity plot profile was determined and the area under the curve 
was calculated which is a measure of the intensity. Using these intensities, the calibration curves 
were plotted as shown in the Figure S1. Adopting similar experimental procedure, the 
fluorescence intensities (red and green) of the conjugated nanoparticle samples were also 
determined. 
8.2.4:  Cellular studies 
The intracellular distribution of surface functionalized NPs into the human pancreatic 
carcinoma cell lines was imaged with an optical microscope (Axiovert 200, Zeiss). Equivalent 
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amounts of MIA PaCa-2 cells were seeded in 35 mm poly L-lysine coated petri dishes with 2 ml 
of cell growth medium containing Dulbecco’s modified essential medium (DMEM), 10% fetal 
bovine serum (FBS) and 5% penicillin. The cells were then incubated for 24 h at 37°C in a 
humidified 5% CO2 atmosphere. Following 24 h of incubation, half the medium was extracted 
out and replaced with fresh medium containing 200 µg of Dex-SPIO-DOX/FITC. After 15 
minutes of further incubation, the cells were washed three times with 1ml of PBS to remove any 
excess and unbound NPs. Then, cells were fixed with 4% glutaraldehyde in PBS at 25°C for 30 
mins. The same procedure was followed with the cells incubated with free DOX and FITC. The 
concentrations of free DOX and FITC were kept approximately identical to that of the respective 
drug and dye, present in Dex-SPIO-DOX/FITC. The experiments were carried out in triplicates.  
8.3: Results and Discussions 
              The structural and magnetic characterizations of the nanoparticles are shown in Chapter 
7. The as-synthesized NPs were coated with dextran (Dex-Fe3O4) and subsequently crosslinked 
using epichlorohydrin (ECH). The crosslinked Fe3O4NPs were grafted with carboxylic groups 
using monochlroacetic (MCA) acid to obtain the carboxymethylated Fe3O4NPs (CMD- Fe3O4). 
The Dox and FITC were attached to the CMD- Fe3O4 NPs through EDC/NHS chemistry. EDC 
and NHS were added to CMD- Fe3O4 NPs suspension to activate the carboxyl groups. Dox was 
added to that mixture followed by the addition of Ethylene diamine hydrochloride (EDA) to react 
with the activated carboxyl groups which provide amine group (-NH2) for further conjugation 
with FITC. The detailed procedure is explained in section 3.2.5 and schematic representation of 
the conjugation steps is shown in Fig. 8.1.  
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Figure 8.1: Schematic representation of the synthesis of the magnetic drug delivery system 
composed of Dextran coated Fe3O4 cores and DOX, FITC conjugations on the surface. 
             The hydrodynamic diameters of the Dex-SPIO and Dex-SPIO-DOX/FITC samples in 
water at 25°C and pH of 7.4 were found to be 100±25 nm and 143±40 nm respectively, whereas 
the respective zeta potential values are -17±3 mV and -9±1 mV. The changes in the size and the 
surface charge upon functionalizing the NPs with DOX/FITC further confirm the conjugation of 
the dye to the Dex-SPIO complex, besides the observation of the association of fluorescence. 
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Using these intensities, the calibration curves were plotted as shown in the Figure 8.2. 
Then following the same experimental procedure, the fluorescence intensities (red and green) of 
the conjugated sample were determined to be 10% and 1% for FITC and Dox respectively. 
Figure 8.2: Calibration fits of (a) FITC and (b) doxorubicin to estimate the drug/dye 
quantification incorporated with Fe3O4 nanoparticles conjugate.  
The calibration plots of fluorescence intensity versus the concentration of the free 
drug/dye are shown in Fig 8.2. From the plots, using the fluorescence intensities (red and green) 
of the conjugated sample the dye/drug loading efficiencies were determined to be 10% and 1% 
for FITC and Dox respectively. To examine the efficacy of DOX on human pancreatic 
carcinoma, experiments were conducted on the MIA PaCa 2 cells both in presence 
(experimental) and absence (control) of the drug. Images of the control and experimental at 6 h 
time point demonstrating the entry of the drug into the nucleus of the malignant cells are shown 
in Figure 4(a).  
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Figure 8.3: (a) The fluorescence microscopy images of MIA PaCa 2 cells incubated with DOX. 
Note cellular entry (especially into the nucleus) of the drug in the 6 h time point and cell 
rounding. The inset shows blebbing of the cells prior to cell death. (b) The fluorescence 
microscopy images of MIA PaCa 2 cells incubated with free DOX + free FITC (control) and 
DOX-FITC conjugated Fe3O4 NPs at 15 mins. Green and red fluorescence represent FITC and 
DOX respectively. Arrow heads indicates the DOX entry into the nucleus. 
The images further demonstrate cell rounding and cell blebbing prior to their death, 
clearly indicating the role of DOX in apoptosis. To examine the cellular internalization of 
synthesized drug-dye-nano carrier conjugation, we conducted a series of fluorescence imaging 
experiments on MIA PaCa-2 cells, grown attached to the tissue culture plates. The inherent 
fluorescence of DOX (red) and FITC (green) were used to track their internalization. For 
comparative studies, control experiments were carried out using the unconjugated DOX and 
FITC. Figure 4(b) shows images collected at 15 minutes for control and experimental samples. 
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The cells exposed to unconjugated DOX/FITC and Dex-SPIO-DOX/FITC show high 
fluorescence intensities on the membrane indicating their strong binding. However, higher 
fluorescence intensities (both green and red) are observed within the cells that were exposed to 
the Dex-SPIO-DOX/FITC, as compared to the cells exposed to the unconjugated DOX/FITC. 
These results indicate a rapid entry of Dex-SPIO-DOX/FITC into the cell than free DOX/FITC 
which might be due to different entrance pathways. It has been well established that the free 
DOX is taken up by the cells only through Fickian diffusion [221,222] while the cellular uptake 
of Dex-SPIO-DOX/FITC is carried out most likely through endocytosis [223,224]. In this 
context, conjugation of the drug with NPs facilitated cellular uptake of DOX through 
endocytosis. For an efficient drug delivery system, not only the rapid uptake by the cancer cell is 
crucial but also the drug release within the cell is of great importance. From Figure 4(b), it is 
clearly observed that the distribution of DOX is very different upon NPs conjugation. In the 
control experiments, the fluorescence intensities on the cell membrane are much higher than in 
the cytoplasm implying that the unconjugated DOX as well as FITC are residing on the cell 
membrane. On the other hand, the distribution of red fluorescence within the cells exposed to 
conjugated DOX is different. The red and green fluorescence are partially separated and the red 
fluorescence seems to accumulate within the nucleus while green fluorescence stays outside of it 
indicating the release of DOX from the conjugation after entering the cells. 
8.7: Conclusions 
In summary, we were able to design and develop a drug delivery platform based on 
Fe3O4NPs as the vehicle for an anti-cancer drug (Dox), attached to a model dye (FITC) for their 
precise tracking. Employing the fluorescence microscopy, we were able to demonstrate that even 
in the absence of any targeting ligand, the internalization of the Dox-FITC-Fe3O4is much higher 
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as compared to the unconjugated Dox, enabling an efficient utilization of the anti-cancer drug.  
In addition to rapid uptake of these NPs by live cells, our results also suggest that upon entering 
the cells, Dox is cleaved from the conjugation, which might be due to the enzymatic reactions 
that occur within the cells, and tends to accumulate in the nuclei fulfilling the major requirement 
for an effective therapeutic system. We hypothesize that incorporation of targeting ligands into 
this system could further enhance its performance and accordingly remodel it to be used in 
different cell types.   
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CHAPTER 9 CONCLUSIONS AND FUTURE WORK 
Magnetic nanoparticles (MNPs), especially superparamagnetic Fe3O4 nanoparticles, have 
attracted a great deal of attention due to their potential multimodal functionality in biomedical 
applications. The research presented in this thesis is focused on exploiting the functionality of 
Fe3O4 nanoparticles for two important biomedical applications; magnetic hyperthermia and drug 
delivery.  
The first part of this thesis focuses on understanding and optimizing the properties of 
Fe3O4 nanoparticles for the maximum efficiency of heat generation. It is well known that the 
SAR, which measures the magnetic hyperthermia efficiency, depends on magnetic properties of 
the particles such as saturation magnetization, magnetic anisotropy, particle size distribution, 
magnetic dipolar interactions, and the rheological properties of the target medium. We 
synthesized Fe3O4 nanoparticles by two different methods, co-precipitation (CP) and the 
hydrothermal (HT) synthesis, exhibiting similar structural and magnetic properties. Despite 
having similar particle size (~ 12 nm) and saturation magnetization (~ 70 emu/g) they show 
drastically different heating rates (SAR) at room temperature ~ 110 W/g (CP sample) and ~ 40 
W/g (HT sample). This observed reduction in SAR has been explained by taking into account the 
dipolar interactions using the so called T* model. Our analysis reveals that HT ferrofluid shows a 
higher effective dipolar interaction and a wider distribution of magnetic core size of MNPs 
compared to that of CP ferrofluid leading to a decrease in SAR. 
Through this study we have been able to determine the effect of particle size, 
polydispersity, magnetic anisotropy and dipolar interactions on the temperature dependent SAR, 
qualitatively and quantitatively, which allow us to design nanoparticles for optimized SAR. For 
example, nanoparticles of 14-15 nm size with a narrow size distribution and lower dipolar 
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interactions would show SAR more than 200 W/g. Furthermore our results show that although 
the HT method of synthesis leads to clustering of nanoparticles with strong dipolar interaction, it 
is very versatile method in tailoring the particle size and distribution and hence further research 
is necessary to figure out a suitable capping agent to avoid clustering of particles during the 
synthesis. 
We have also investigated the effect of the Gd-doping on the magnetic properties of 
nanoparticles and the associated magnetic hyperthermia response of the ferrofluids. The 
possibility of using Gd doped Fe3O4 nanoparticles as a dual modal T1-T2 contrast agent is being 
currently explored by others. However, the possibility of using this doped system for magnetic 
hyperthermia is not explored well. Both Gd-doped and un-doped iron oxide nanoparticles were 
synthesized using co-precipitation method and coated with dextran. Our analysis on structural 
and magnetic characterization data reveals that Gd (2.5 wt. %)-doping of Fe3O4 nanoparticles 
leads to an increase in particle size and a reduced saturation magnetization. MHT experiments 
revels that Gd-doped Fe3O4 exhibits a similar SAR value as that of un-doped Fe3O4 ferrofluid. 
Our magnetic hyperthermia research demonstrates that this material is a potential candidate for 
theronostics for multimodal contrast imaging and cancer treatment by hyperthermia. 
 From the analysis of temperature dependent SAR curves of Gd-doped Fe3O4 ferrofluids, 
we found that the magnetocrystalline anisotropy (K) was found to decrease by 50% upon Gd-
doping. Among the very little literature on SAR of Gd-doped Fe3O4 nanoparticles present, a 
recent study done by Douglas et. al [225] reports a SAR of 3.7±0.6 W/g Fe
-1 
at H0 = 3 kA/m and f 
=111 kHz for 2% Gd doping. The authors attribute this observed enhancement in SAR to an 
increase in magnetic anisotropy of Fe3O4 nanoparticles upon Gd doping, in contradiction to our 
observation of a decrease in K dut to Gd doping. Further research is necessary to resolve this 
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contradiction and further optimize the amount of Gd-doping to enhance SAR for cancer 
treatment, as well as for a dual modal T1-T2 contrast agent. 
We have made a comparative study of two different biocompatible coatings, dextran and 
CA, on the colloidal and magnetic properties of Fe3O4nanoparticles as well as their impact on 
magnetic hyperthermia efficiency was studied. Both the ferrofluids show similar magnetic and 
hyperthermia properties, indicating that these surface modifications have no effect on their 
performance. However, our concentration dependent magnetic hyperthermia results indicate that 
the dilution of the sample should be done with extensive care as it may promote cluster 
formation which in turn reduces the SAR value.  
Moreover, upon exposure to cell growth medium that mimics the physiological 
environment, formation of corona was observed for both dextran and CA coated nanoparticles as 
seen from the hydrodynamic size measurements. It was observed that in CA coated particles 
where, this protein corona forms faster, in several minutes to hours, causes aggregations in 
solution and reduces SAR by ~ 45%. Dextran coated nanoparticles show a better stability at least 
within first 3-6 hours upon exposure to the proteins in the cell growth medium exhibiting 
excellent performance in both water and simulated physiological conditions. Furthermore, the 
cytotoxicity studies done on human pancreatic cancer cells indicate that both dextran and CA 
coated Fe3O4 ferrofluids are nontoxic to the cells at or below 100 µg/mL concentration. Though 
further in vivo study is necessary in the future, these results imply that the dextran coated Fe3O4 
dispersion could maintain their high heating capacity in physiological environments while CA 
coating require further surface modification to reduce the non-specific protein adsorption. 
However, the rapid formation of protein corona accelerates the endocytosis pathway leading to 
the rapid entry of the nanoparticles into the cells which is a crucial factor for applications such as 
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drug delivery and magnetic hyperthermia for cancer treatment [226-228]. Therefore it would be 
necessary to perform in-vitro hyperthermia for these different coatings to investigate the effect of 
the protein corona, which depends on the surface properties of the nanoparticles, on the 
hyperthermia efficiency.  
We also have successfully functionalized dextran coated Fe3O4 nanoparticles with 
fluorescence dye, FITC, to investigate their binding and distribution in Mia PaCa-2 human 
pancreatic cancer cells. Our results done on investigating the traffic, distribution, and 
cytotoxicity, associated with these Fe3O4 nanoparticles, demonstrate that there is a time-
dependent distribution of these nanoparticles into different cellular compartments. It will be 
interesting to explore the possibility of incorporating the magnetic hyperthermia with these 
nanoparticles, for an enhanced cellular uptake as the magnetic heating may influence the 
dynamics of nanoparticles through the cell membrane.  
Furthermore, we were able to design and develop a drug delivery platform based on 
Fe3O4 NPs as the vehicle for an anti-cancer drug (Dox), attached to a model dye (FITC) for their 
precise tracking. Employing the fluorescence microscopy, we were able to demonstrate that even 
in the absence of any targeting ligand, the internalization of the Dox-FITC-Fe3O4is much higher 
as compared to the unconjugated Dox, enabling an efficient utilization of the anti-cancer drug.  
In addition to rapid uptake of these NPs by live cells, our results also suggest that upon entering 
the cells, Dox is cleaved from the conjugation, which might be due to the enzymatic reactions 
that occur within the cells, and tends to accumulate in the nuclei fulfilling the major requirement 
for an effective therapeutic system. We hypothesize that incorporation of targeting ligands into 
this system could further enhance its performance and accordingly remodel it to be used in 
different cell types.   
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In recent years, magnetic nanoparticles (MNPs), especially superparamagnetic 
Fe3O4nanoparticles, have attracted a great deal of attention because of their potential applications 
in biomedicine. Among the other applications, Magnetic hyperthermia (MHT), where localized 
heating is generated by means of relaxation processes in MNPs when subjected to a radio 
frequency magnetic field, has a great potential as a non-invasive cancer therapy treatment. 
Specific absorption rate (SAR), which measures the efficiency of heat generation, depends on 
magnetic properties of the particles such as saturation magnetization (Ms), magnetic anisotropy 
(K), particle size distribution, magnetic dipolar interactions, and the rheological properties of the 
target medium.We have investigated MHT in two Fe3O4 ferrofluids prepared by co-precipitation 
(CP) and hydrothermal (HT) synthesis methods showing similar physical particle size 
distribution and Ms, but very different SAR ~ 110 W/g and ~ 40 W/g at room temperature. This 
observed reduction in SAR has been explained by taking the dipolar interactions into account 
using the so called T* model. Our analysis reveals that HT ferrofluid shows an order of 
magnitude higher effective dipolar interaction and a wider distribution of magnetic core size of 
MNPs compared to that of CP ferrofluid.  
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We have studied dextran coated Gd-doped Fe3O4 nanoparticles as a potential candidate in 
theronostics for multimodal contrast imaging and cancer treatment by hyperthermia. The effect 
of surfactant on the MHT efficiency and cytotoxicity on human pancreatic cancer cells was 
explored as well. Though further in vivo study is necessary in the future, these results imply that 
the dextran coated Fe3O4 dispersion could maintain their high heating capacity in physiological 
environments while citric acid coating require further surface modification to reduce the non-
specific protein adsorption. We have also investigated the traffic, distribution, and cytotoxicity, 
associated with dextran functionalized FITC conjugated Fe3O4 nanoparticles, and our results 
demonstrate that there is a time-dependent distribution of these nanoparticles into different 
cellular compartments. Moreover, a novel conjugation of anti-cancer drug, Doxorubicin (Dox) 
with a labeling dye (FITC) onto dextran coated Fe3O4 nanoparticles was developed using 
existing EDC/NHS technique for specific drug targeting. The experiments on this unique drug-
dye dual conjugation with human pancreatic cancer cell line (MIA PaCa-2) show that association 
of Dox onto the surface of nanoparticles enhances its penetration into the cancer cells as 
compared to the unconjugated drug while releasing Dox into the nucleus of the malignant cells. 
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